L Number	Hits	Search Text	DB	Time stamp
1	38	(heparinase adj III) or (heparinase adj "3")	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 12:57
7	1	((heparinase adj III) or (heparinase adj "3")) near3 (mutant or mutation)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 12:57
13	3	((heparinase adj III) or (heparinase adj "3")) near3 (product)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 12:57
19	3	(((heparinase adj III) or (heparinase adj "3")) near3 (mutant or mutation)) or (((heparinase adj III) or (heparinase adj "3")) near3 (product))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:00
25	11	((heparinase adj III) or (heparinase adj "3")) near3 (activity or kinetic or kcat)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:01
31	4283	(((heparinase adj III) or (heparinase adj "3")) near3 (mutant or mutation)) or "111"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:02
37	11	(((heparinase adj III) or (heparinase adj "3")) near3 (mutant or mutation)) or (((heparinase adj III) or (heparinase adj "3")) near3 (activity or kinetic or kcat))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:24
43	85	((heparinase adj III) or (heparinase adj "3")) or (heparin adj like adj glycosaminoglycans)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:25
49	2	(((heparinase adj III) or (heparinase adj "3")) or (heparin adj like adj glycosaminoglycans)) near3 (targeting adj molecule)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:25
55	1	(((heparinase adj III) or (heparinase adj "3")) or (heparin adj like adj glycosaminoglycans)) near3 (target)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:26
61	3	((((heparinase adj III) or (heparinase adj "3")) or (heparin adj like adj glycosaminoglycans)) near3 (targeting adj molecule)) or ((((heparinase adj III) or (heparinase adj "3")) or (heparin adj like adj glycosaminoglycans)) near3 (target))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/11/25 13:26

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653sxs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28	Oct 21	EVENTLINE has been reloaded
NEWS 29	Oct 24	BEILSTEIN adds new search fields
NEWS 30	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 32	Nov 18	DKILIT has been renamed APOLLIT
NEWS 33	Nov 25	More calculated properties added to REGISTRY

NEWS EXPRESS	October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:13:45 ON 25 NOV 2002

=> File bioscience health medicine meetings pharmacology research toxicology
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'ADISALERTS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'AGRICOLA' ENTERED AT 14:14:23 ON 25 NOV 2002

FILE 'ANABSTR' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 14:14:23 ON 25 NOV 2002
(c) 2002 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHDS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHNO' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 14:14:23 ON 25 NOV 2002

FILE 'CAPLUS' ENTERED AT 14:14:23 ON 25 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 DECHEMA eV

FILE 'CEN' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:14:23 ON 25 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DDFB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DDFU' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DGENE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'DRUGB' ACCESS NOT AUTHORIZED

FILE 'DRUGLAUNCH' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'DRUGU' ACCESS NOT AUTHORIZED

FILE 'DRUGUPDATES' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:14:23 ON 25 NOV 2002

FILE 'FOMAD' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:14:23 ON 25 NOV 2002

FILE 'HEALSAFE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:14:23 ON 25 NOV 2002

FILE 'NIOSHTIC' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:14:23 ON 25 NOV 2002
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2002)

FILE 'OCEAN' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 14:14:23 ON 25 NOV 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PHAR' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 14:14:23 ON 25 NOV 2002
Copyright 2002 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'SYNTHLINE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 ACS

FILE 'USPATFULL' ENTERED AT 14:14:23 ON 25 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:14:23 ON 25 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'VETU' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CBNB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CHEMLIST' ENTERED AT 14:14:23 ON 25 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CSNB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ENERGY' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 USDOE for the IEA-Energy Technology Data Exchange (ETDE)

FILE 'HSDB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 NATIONAL LIBRARY OF MEDICINE

FILE 'INIS' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 American Society of Hospital Pharmacists (ASHP)

FILE 'MSDS-CCOHS' ENTERED AT 14:14:23 ON 25 NOV 2002
Copyright Notice: Permission to copy is not required for this file

FILE 'MSDS-OHS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 MDL INFORMATION SYSTEMS (MDL)

FILE 'NAPRALERT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Board of Trustees of the University of Illinois,
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.

FILE 'POLLUAB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'RTECS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government (DOC)

FILE '1MOBILITY' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Society of Automotive Engineers, Inc.

FILE 'COMPENDEX' ENTERED AT 14:14:23 ON 25 NOV 2002
Compendex Compilation and Indexing (C) 2002
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'COMPUAB' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CONF' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 FIZ Karlsruhe

FILE 'ELCOM' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EVENTLINE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 EXCERPTA MEDICA MEDICAL COMMUNICATIONS B.V. (EMMC)

FILE 'IMSDRUGCONF' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd.

FILE 'ISMEC' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PAPERCHEM2' ENTERED AT 14:14:23 ON 25 NOV 2002
Paperchem2 compilation and indexing (C) 2002
Elsevier Engineering Information Inc. All rights reserved.

FILE 'SOLIDSTATE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'BABS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (c) 2002 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'DIOGENES' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 FOI Services, Inc. (FOI)

FILE 'INVESTEXT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Thomson Financial Services, Inc. (TFS)

FILE 'USAN' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 U.S. Pharmacopeial Convention, Inc. (USPC)

FILE 'DKF' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Dokumentation Kraftfahrwesen e.V., Germany

FILE 'FORIS' ENTERED AT 14:14:23 ON 25 NOV 2002

```
COPYRIGHT (C) 2002 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'FORKAT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Bundesministerium fuer Bildung,
Wissenschaft, Forschung und Technologie (bmb+f)

FILE 'RUSSCI' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Andrigal Ltd.

FILE 'SOLIS' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Informationszentrum Sozialwissenschaften, Bonn (IZS)

FILE 'UFORDAT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Umweltbundesamt, D-14191 Berlin (UBA)

FILE 'AQUIRE' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 US Environmental Protection Agency (EPA)

FILE 'ULIDAT' ENTERED AT 14:14:23 ON 25 NOV 2002
COPYRIGHT (C) 2002 Umweltbundesamt, D-14191 Berlin (UBA)

=> s (heparinase III) or (heparinase 3)
  21 FILES SEARCHED...
  39 FILES SEARCHED...
  56 FILES SEARCHED...
  67 FILES SEARCHED...
  84 FILES SEARCHED...
L1          539 (HEPARINASE III) OR (HEPARINASE 3)

=> s l1 adj3 (mutant or mutation)
MISSING OPERATOR L1 ADJ3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=>  s l1 (adj3) (mutant or mutation)
MISSING OPERATOR 'L95 (ADJ3'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 (adj3) mutant (or) mutation
MISSING OPERATOR 'L95 (ADJ3'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l1 adj3 mutant
MISSING OPERATOR L1 ADJ3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (3A) (mutant or mutation)
MISSING TERM BEFORE '(3A'
Search expressions cannot begin with operators.

=>  s l1 (3A) (mutant or mutation)
  28 FILES SEARCHED...
  55 FILES SEARCHED...
  90 FILES SEARCHED...
L2            4 L1 (3A) (MUTANT OR MUTATION)

=> s l1 (3A) modified
  38 FILES SEARCHED...
  82 FILES SEARCHED...
```

```
L3          10 L1 (3A) MODIFIED

=> s l2 or l3
  40 FILES SEARCHED...
L4          10 L2 OR L3

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONF, PHAR, PHARMAML, SYNTHLINE, CHEMLIST, HSDB, MSDS-CCOHS, MSDS-OHS,
RTECS, CONF, EVENTLINE, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN, FORIS, FORKAT,
UFORDAT, AQUIRE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'CAPLUS, DGENE, IFIPAT, TOXCENTER, USPATFULL, WPINDEX'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L4
L5            7 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)

=> d l5 1-7 bib ab

L5   ANSWER 1 OF 7  IFIPAT  COPYRIGHT 2002 IFI         DUPLICATE 1
AN    10179096  IFIPAT;IFIUDB;IFICDB
TI    HEPARINASE III AND USES THEREOF
INF   El-Shabrawi; Yosuf, Graz, AT
      Holley; Kristine, Boston, MA, US
      Liu; Dongfang, Framingham, MA, US
      Pojasek; Kevin, Cambridge, MA, US
      Sasisekharan; Ram, Cambridge, MA, US
      Shriver; Zachary, Cambridge, MA, US
      Venkataraman; Ganesh, Wallham, MA, US
IN    El-Shabrawi Yosuf (AT); Holley Kristine; Liu Dongfang; Pojasek Kevin;
      Sasisekharan Ram; Shriver Zachary; Venkataraman Ganesh
PAF   Unassigned
PA    Unassigned Or Assigned To Individual (68000)
AG    Helen C. Lockhart c/o Wolf, Greenfield & Sacks, P.C., 600 Atlantic
      Avenue, Boston, MA 02210, US
PI    US 2002122793   A1  20020905
AI    US 2001-802285      20010308
PRAI  US 2000-187846P     20000308 (Provisional)
FI    US 2002122793       20020905
DT    Utility; Patent Application - First Publication
FS    CHEMICAL
      APPLICATION
GOVI  (0002) Some aspects of the invention were made with government support
      under NIH Contract No. GM57073. The government may have certain rights in
      the invention.
CLMN  60
GI     16 Figure(s).
     FIG. 1 is a graph depicting the effect of DEPC inactivation of heparinase
      III on rate constant.
     FIG. 2 is a graph depicting the pH dependence of the second order rate
      constant of inactivation upon incubation of heparinase III with varying
      concentrations of DEPC.
     FIG. 3 is a graph depicting the quantification of DEPC-modified
      histidine residues in heparinase III over a period of
      time.
     FIG. 4 is a graph depicting the substrate protection of heparinase III
      inactivation by DEPC III.
     FIG. 5 is a reverse phase HPLC profile of a lys-C digest of heparinase III
      which was not exposed to DEPC (top panel) and a peptide profile of
```

heparinase III labeled with DEPC (bottom panel).

FIG. 6 is a series of graphs depicting SAX analysis of exhaustive heparinase III digests of heparan sulfate. Heparan sulfate was digested with either heparinase III from F. heparinum (panel A), recombinant **heparinase III** (panel B), H295A **mutant** enzyme (panel C), H510A mutant enzyme (panel D), or the H105A mutant enzyme (panel E).

FIG. 7 depicts a circular dichroism analysis of recombinant **heparinase III** and the H295A **mutant** enzyme, and the H510A mutant enzyme.

FIG. 8 is a graph depicting tumor volume in mice, as well as mice treated with heparinase I.

FIG. 9 is a bar graph depicting number of lung nodules that developed 13 days after tail vein injection of B16 BL6 cells. The cells were either treated with PBS, heparinase I, or heparinase III.

FIG. 10, panel A, depicts the tumor volume of mice that were treated with GAG fragments generated from treatment of B16 BL6 cells with either heparinase I, heparinase III, or PBS or fragments generated from heparinase I treatment of LLC cells. Tumor volume was measured over time between 7 and 15 days postinjection of the tumor cells.

FIG. 10, panel B is a bar graph which quantitates the number of lung nodules of the mice described in panel A.

FIG. 11 is a bar graph depicting the effect on B16 cellular migration and invasion of transfection with antisense 2OST in pcDNA3.1.

FIG. 12 shows bar graphs depicting the ability of the transfected cells of FIG. 12 to develop into primary tumors as assessed by mean tumor volume (12a) and tumor weight (12b).

FIG. 13 depicts the results of compositional analysis of HLGAG saccharide fragments released from B16BL6 cells.

FIG. 14 is a bar graph depicting FGF2 signaling modulated by HLGAG fragments

FIG. 15 is a table (15a) and a schematic depicting the modulation of FGF2 activity in vivo by B16BL6 fragments (15b).

AB The invention relates to **heparinase III** and **mutants** thereof. **Modified** forms of **heparinase III** having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
AN 2001:676971 CAPLUS
DN 135:221282
TI Use of heparinase III in cancer treatment and inhibition of tumor cell growth
IN Dongfang, Liu; Pojasek, Kevin; Shriver, Zachary; Holley, Kristine; El-Shabrawi, Yosuf; Venkataraman, Ganesh; Sasisekharan, Ram
PA Massachusetts Institute of Technology, USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066772	A2	20010913	WO 2001-US7464	20010308
	WO 2001066772	A3	20020502		

W: AU, CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

US 2002122793 A1 20020905 US 2001-802285 20010308

PRAI US 2000-187846P P 20000308

AB The invention relates to **heparinase III** and **mutants** thereof. **Modified** forms of **heparinase III** having reduced enzymic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a soln., inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymic cleavage by heparinase III of HLGAGs.

L5 ANSWER 3 OF 7 USPATFULL

AN 1999:75550 USPATFULL

TI Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum

IN Su, Hongsheng, Lonqnenil, Canada
Blain, Francoise, Que, Canada
Bennett, Clark, Quebec, Canada
Gu, Kangfu, Quebec, Canada
Zimmermann, Joseph, Elm Grove, WI, United States
Musil, Roy, Carlsbad, CA, United States

PA IBEX Technologies Corp., Malvern, PA, United States (U.S. corporation)

PI US 5919693 19990706

AI US 1997-900951 19970725 (8)

RLI Division of Ser. No. US 1994-258639, filed on 10 Jun 1994, now patented, Pat. No. US 5681733

DT Utility

FS Granted

EXNAM Primary Examiner: Prouty, Rebecca E.

LREP Hale & Dorr LLP

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 1605

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes the isolation and sequence of genes from Flavobacterium heparinum encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of F. heparinum. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to Flavobacterium heparinum proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.

L5 ANSWER 4 OF 7 USPATFULL

AN 97:99186 USPATFULL

TI Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum

IN Su, Hongsheng, Longueuil, Canada
Blain, Francoise, Mtl., Canada
Bennett, Clark, Pierrefonds, Canada
Gu, Kangfu, D.D.O., Canada
Zimmermann, Joseph, Elm Grove, WI, United States
Musil, Roy, Carlsbad, CA, United States

PA Ibex Technologies, Montreal, Canada (non-U.S. corporation)

PI US 5681733 19971028
AI US 1994-258639 19940610 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Prouty, Rebecca E.
LREP Hale and Dorr LLP
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes the isolation and sequence of genes from Flavobacterium heparinum encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of F. heparinum. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to Flavobacterium heparinum proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.

L5 ANSWER 5 OF 7 DGENE (C) 2002 THOMSON DERWENT
AN ABB06932 Peptide DGENE
TI Novel **modified heparinase III** polypeptides useful for treating cancer and inhibiting tumor cell growth and/or metastasis, sequencing heparin-like glycosaminoglycans, and removing active heparan sulfate from solution -
IN Dongfang L; Pojasek K; Shriver Z; Holley K; El-Shabrawi Y; Venkataraman G; Sasisekharan R
PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
PI WO 2001066772 A2 20010913 94p
AI WO 2001-US7464 20010308
PRAI US 2000-187846P 20000308
DT Patent
LA English
OS 2001-596840 [67]
AB The present sequence represents a Flavobacterium heparinum heparinase III (EC 4.2.2.8) peptide, which is used in an example from the present invention. The present invention describes a substantially pure **heparinase III** (H) (**modified** (H)) (I) having the amino acid sequence of mature Flavobacterium heparinum (see ABB06931), or having conservative substitutions within residues non-essential to enzymatic function such as His residue at positions 36, 105, 110, 139, 152, 225, 234, 241, 424, 469 or 539 that is substituted by Ala, Ser, Tyr, Thr or Lys residue. (I) has antitumour, cytostatic, antipsoriatic, antiarthritic, vasotropic, gynaecological, antiinflammatory, anticoagulant, ophthalmological, antidiabetic and cerebroprotective activities, and can be used as: a tumour cell proliferation or metastasis inhibitor; a neovascularisation or angiogenesis inhibitor; and a heparin-like glycosaminoglycans (HLGAG) cleavage mediator. (I) is useful for preventing proliferation of tumours such as prostate tumour or melanoma, and for preventing tumour cell metastasis. (I) is also useful for treating arthritis, psoriasis, diabetic retinopathy, chronic inflammation, scleroderma, prolonged mensuration and bleeding by inhibiting neovascularisation or angiogenesis. It is also useful for treating disorders associated with coagulation and so can be used in treating cerebral ischaemia and thromboembolic stroke. N.B. The sequence data for this patent is not represented in the printed specification but is based on sequence

information supplied by the European Patent Office.

L5 ANSWER 6 OF 7 DGENE (C) 2002 THOMSON DERWENT
AN ABB06931 Protein DGENE
TI Novel **modified heparinase III** polypeptides useful for treating cancer and inhibiting tumor cell growth and/or metastasis, sequencing heparin-like glycosaminoglycans, and removing active heparan sulfate from solution -
IN Dongfang L; Pojasek K; Shriver Z; Holley K; El-Shabrawi Y; Venkataraman G; Sasisekharan R
PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
PI WO 2001066772 A2 20010913 94p
AI WO 2001-US7464 20010308
PRAI US 2000-187846P 20000308
DT Patent
LA English
OS 2001-596840 [67]
AB The present sequence represents Flavobacterium heparinum heparinase III (EC 4.2.2.8). The present invention describes a substantially pure **heparinase III** (H) (**modified** (H)) (I) having the amino acid sequence of mature Flavobacterium heparinum (see ABB06931), or having conservative substitutions within residues non-essential to enzymatic function such as His residue at positions 36, 105, 110, 139, 152, 225, 234, 241, 424, 469 or 539 that is substituted by Ala, Ser, Tyr, Thr or Lys residue. (I) has antitumour, cytostatic, antipsoriatic, antiarthritic, vasotropic, gynaecological, antiinflammatory, anticoagulant, ophthalmological, antidiabetic and cerebroprotective activities, and can be used as: a tumour cell proliferation or metastasis inhibitor; a neovascularisation or angiogenesis inhibitor; and a heparin-like glycosaminoglycans (HLGAG) cleavage mediator. (I) is useful for preventing proliferation of tumours such as prostate tumour or melanoma, and for preventing tumour cell metastasis. (I) is also useful for treating arthritis, psoriasis, diabetic retinopathy, chronic inflammation, scleroderma, prolonged mensuration and bleeding by inhibiting neovascularisation or angiogenesis. It is also useful for treating disorders associated with coagulation and so can be used in treating cerebral ischaemia and thromboembolic stroke. N.B. The sequence data for this patent is not represented in the printed specification but is based on sequence information supplied by the European Patent Office.

L5 ANSWER 7 OF 7 DGENE (C) 2002 THOMSON DERWENT
AN ABL50563 DNA DGENE
TI Novel **modified heparinase III** polypeptides useful for treating cancer and inhibiting tumor cell growth and/or metastasis, sequencing heparin-like glycosaminoglycans, and removing active heparan sulfate from solution -
IN Dongfang L; Pojasek K; Shriver Z; Holley K; El-Shabrawi Y; Venkataraman G; Sasisekharan R
PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
PI WO 2001066772 A2 20010913 94p
AI WO 2001-US7464 20010308
PRAI US 2000-187846P 20000308
DT Patent
LA English
OS 2001-596840 [67]
AB The present sequence encodes Flavobacterium heparinum heparinase III (EC 4.2.2.8). The present invention describes a substantially pure **heparinase III** (H) (**modified** (H)) (I) having the amino acid sequence of mature Flavobacterium heparinum (see ABB06931), or having conservative substitutions within residues non-essential to enzymatic function such as His residue at positions 36,

105, 110, 139, 152, 225, 234, 241, 424, 469 or 539 that is substituted by Ala, Ser, Tyr, Thr or Lys residue. (I) has antitumour, cytostatic, antipsoriatic, antiarthritic, vasotropic, gynaecological, antiinflammatory, anticoagulant, ophthalmological, antidiabetic and cerebroprotective activities, and can be used as: a tumour cell proliferation or metastasis inhibitor; a neovascularisation or angiogenesis inhibitor; and a heparin-like glycosaminoglycans (HLGAG) cleavage mediator. (I) is useful for preventing proliferation of tumours such as prostate tumour or melanoma, and for preventing tumour cell metastasis. (I) is also useful for treating arthritis, psoriasis, diabetic retinopathy, chronic inflammation, scleroderma, prolonged mensuration and bleeding by inhibiting neovascularisation or angiogenesis. It is also useful for treating disorders associated with coagulation and so can be used in treating cerebral ischaemia and thromboembolic stroke. N.B. The sequence data for this patent is not represented in the printed specification but is based on sequence information supplied by the European Patent Office.

```
=>
<------User Break------>

=>
<------User Break------>

=> s l1 or (heparin like glycosaminoglycan)
  22 FILES SEARCHED...
  44 FILES SEARCHED...
  70 FILES SEARCHED...
L6        1233 L1 OR (HEPARIN LIKE GLYCOSAMINOGLYCAN)

=> s l6 and (targeting molecule) or (target)
  23 FILES SEARCHED...
  45 FILES SEARCHED...
  64 FILES SEARCHED...
  91 FILES SEARCHED...
L7     4637596 L6 AND (TARGETING MOLECULE) OR (TARGET)

=> s l6 and (targeting molecule)
  31 FILES SEARCHED...
  60 FILES SEARCHED...
L8           6 L6 AND (TARGETING MOLECULE)

=> s l6 and target
  36 FILES SEARCHED...
  74 FILES SEARCHED...
 75% OF LIMIT FOR L#S REACHED
L9          73 L6 AND TARGET

=> s l6 and targeting
  46 FILES SEARCHED...
  85 FILES SEARCHED...
L10         44 L6 AND TARGETING

=> s l8 or l9 or l10
  35 FILES SEARCHED...
  89 FILES SEARCHED...
 95% OF LIMIT FOR L#S REACHED
L11         98 L8 OR L9 OR L10

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
```

ENTER L# LIST OR (END):l11
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET, MEDICONF, PHAR, PHARMAML, SYNTHLINE, CHEMLIST, HSDB, MSDS-CCOHS, MSDS-OHS, RTECS, CONF, EVENTLINE, IMSDRUGCONF, DIOGENES, INVESTEXT, USAN, FORIS, FORKAT, UFORDAT, AQUIRE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'AGRICOLA, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, DDFU, EMBASE, ESBIOBASE, FEDRIP, GENBANK, IFIPAT, LIFESCI, MEDLINE, PASCAL, SCISEARCH, USPATFULL, USPAT2, WPINDEX, MSDS-OHS, NLDB'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L11
L12 64 DUPLICATE REMOVE L11 (34 DUPLICATES REMOVED)

=> d l12 1-64 bib ab
NO VALID FORMATS ENTERED FOR FILE 'GENBANK'
In a multifile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):filedefault

L12 ANSWER 1 OF 64 COPYRIGHT 2002 Gale Group

AN 2002:44543 NLDB
TI Researchers Tailor Cancer Cells' Sugar Jackets To Inhibit Tumor Growth.
SO Cancer Weekly, (12 Feb 2002) pp. 11.
ISSN: 1532-4567.
PB NewsRX
DT Newsletter
LA English
WC 562

L12 ANSWER 2 OF 64 IFIPAT COPYRIGHT 2002 IFI DUPLICATE 1
AN 10179096 IFIPAT;IFIUDB;IFICDB
TI **HEPARINASE III** AND USES THEREOF
IN El-Shabrawi Yosuf (AT); Holley Kristine; Liu Dongfang; Pojasek Kevin; Sasisekharan Ram; Shriver Zachary; Venkataraman Ganesh
PA Unassigned Or Assigned To Individual (68000)
PI US 2002122793 A1 20020905
AI US 2001-802285 20010308
PRAI US 2000-187846P 20000308 (Provisional)
FI US 2002122793 20020905
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 60
GI 16 Figure(s).
FIG. 1 is a graph depicting the effect of DEPC inactivation of **heparinase III** on rate constant.
FIG. 2 is a graph depicting the pH dependence of the second order rate constant of inactivation upon incubation of **heparinase III** with varying concentrations of DEPC.
FIG. 3 is a graph depicting the quantification of DEPC-modified histidine residues in **heparinase III** over a period of time.
FIG. 4 is a graph depicting the substrate protection of **heparinase III** inactivation by DEPC III.
FIG. 5 is a reverse phase HPLC profile of a lys-C digest of **heparinase III** which was not exposed to DEPC (top panel) and a peptide profile of **heparinase III** labeled with DEPC (bottom panel).
FIG. 6 is a series of graphs depicting SAX analysis of exhaustive

heparinase III digests of heparan sulfate. Heparan sulfate was digested with either **heparinase III** from F. heparinum (panel A), recombinant **heparinase III** (panel B), H295A mutant enzyme (panel C), H510A mutant enzyme (panel D), or the H105A mutant enzyme (panel E).

FIG. 7 depicts a circular dichroism analysis of recombinant **heparinase III** and the H295A mutant enzyme, and the H510A mutant enzyme.

FIG. 8 is a graph depicting tumor volume in mice, as well as mice treated with heparinase I.

FIG. 9 is a bar graph depicting number of lung nodules that developed 13 days after tail vein injection of B16 BL6 cells. The cells were either treated with PBS, heparinase I, or **heparinase III**.

FIG. 10, panel A, depicts the tumor volume of mice that were treated with GAG fragments generated from treatment of B16 BL6 cells with either heparinase I, **heparinase III**, or PBS or fragments generated from heparinase I treatment of LLC cells. Tumor volume was measured over time between 7 and 15 days postinjection of the tumor cells.

FIG. 10, panel B is a bar graph which quantitates the number of lung nodules of the mice described in panel A.

FIG. 11 is a bar graph depicting the effect on B16 cellular migration and invasion of transfection with antisense 20ST in pcDNA3.1.

FIG. 12 shows bar graphs depicting the ability of the transfected cells of FIG. 12 to develop into primary tumors as assessed by mean tumor volume (12a) and tumor weight (12b).

FIG. 13 depicts the results of compositional analysis of HLGAG saccharide fragments released from B16BL6 cells.

FIG. 14 is a bar graph depicting FGF2 signaling modulated by HLGAG fragments

FIG. 15 is a table (15a) and a schematic depicting the modulation of FGF2 activity in vivo by B16BL6 fragments (15b).

L12 ANSWER 3 OF 64 USPATFULL DUPLICATE 2
AN 2002:250778 USPATFULL
TI COMPOSITIONS AND METHODS FOR ALTERING CELL MIGRATION
IN MILLIS, ALBERT J. T., SCHENECTADY, NY, UNITED STATES
PI US 2002136716 A1 20020926
US 6464975 B2 20021015
AI US 1999-459749 A1 19991210 (9)
PRAI US 1998-111856P 19981211 (60)
DT Utility
FS APPLICATION
LN.CNT 964
INCL INCLM: 424/130.100
INCLS: 424/155.100; 530/387.100; 530/388.850; 435/007.230
NCL NCLM: 424/139.100
NCLS: 530/387.100; 530/389.200; 424/130.100
IC [7]
ICM: G01N033-574
ICS: A61K038-00; A61K039-395; C07K016-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 64 USPATFULL DUPLICATE 3
AN 2002:126346 USPATFULL
TI COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA
IN YACOBY-ZEEVI, ORON, MEITAR, ISRAEL
PI US 2002064858 A1 20020530
US 6423312 B2 20020723
AI US 1998-140888 A1 19980827 (9)
RLI Continuation of Ser. No. US 1998-46475, filed on 25 Mar 1998, PATENTED

Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, PATENTED
DT Utility
FS APPLICATION
LN.CNT 1131
INCL INCLM: 435/232.000
NCL NCLM: 424/094.500
NCLS: 424/094.100; 424/094.610; 424/094.620; 435/183.000; 435/200.000; 435/209.000; 435/252.100
IC [7]
ICM: C12N009-88
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 64 USPATFULL
AN 2002:301598 USPATFULL
TI Methods and products related to low molecular weight heparin
IN Sasisekharan, Ram, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Waltham, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Liu, Dongfang, Framingham, MA, UNITED STATES
Sundaram, Mallikarjun, Brighton, MA, UNITED STATES
Qi, Yiwei, Framingham, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA (U.S. corporation)
PI US 2002169143 A1 20021114
AI US 2001-951138 A1 20010912 (9)
PRAI US 2000-231994P 20000912 (60)
DT Utility
FS APPLICATION
LN.CNT 3597
INCL INCLM: 514/054.000
INCLS: 436/094.000
NCL NCLM: 514/054.000
NCLS: 436/094.000
IC [7]
ICM: A61K031-715
ICS: G01N033-00

L12 ANSWER 6 OF 64 USPATFULL
AN 2002:272827 USPATFULL
TI Antibody PTI-HS7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
IN Castillo, Gerardo, Seattle, WA, UNITED STATES
Choi, Paula Y., Bothell, WA, UNITED STATES
Cummings, Joel A., Seattle, WA, UNITED STATES
Snow, Alan D., Lynnwood, WA, UNITED STATES
PI US 2002150948 A1 20021017
AI US 2001-53474 A1 20011102 (10)
PRAI US 2000-245951P 20001103 (60)
DT Utility
FS APPLICATION
LN.CNT 1260
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 64 USPATFULL
AN 2002:250783 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, UNITED STATES
Tabor, Kelly H., Hillsborough, CA, UNITED STATES

PI US 2002136721 A1 20020926
AI US 2001-995693 A1 20011129 (9)
RLI Continuation of Ser. No. US 2000-669971, filed on 26 Sep 2000, PENDING
Continuation of Ser. No. US 1998-952235, filed on 17 Feb 1998, GRANTED, Pat. No. US 6207152 A 371 of International Ser. No. WO 1996-US8094, filed on 31 May 1996, UNKNOWN A 371 of International Ser. No. US 1995-460368, filed on 2 Jun 1995, GRANTED, Pat. No. US 5686292
DT Utility
FS APPLICATION
LN.CNT 2799
INCL INCLM: 424/143.100
INCLS: 530/388.220; 435/069.100; 435/326.000; 536/023.530
NCL NCLM: 424/143.100
NCLS: 530/388.220; 435/069.100; 435/326.000; 536/023.530
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 64 USPATFULL
AN 2002:250772 USPATFULL
TI Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
IN Samulski, Richard Jude, Chapel Hill, NC, UNITED STATES
Summerford, Candace, Chapel Hill, NC, UNITED STATES
PA The University, Chapel Hill, NC (U.S. corporation)
PI US 2002136710 A1 20020926
AI US 2002-102314 A1 20020320 (10)
RLI Division of Ser. No. US 1999-228203, filed on 11 Jan 1999, PENDING
PRAI US 1998-71210P 19980112 (60)
DT Utility
FS APPLICATION
LN.CNT 2796
INCL INCLM: 424/093.210
INCLS: 514/044.000; 514/056.000; 435/456.000
NCL NCLM: 424/093.210
NCLS: 514/044.000; 514/056.000; 435/456.000
IC [7]
ICM: A61K048-00
ICS: A61K031-727; C12N015-861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 64 USPATFULL
AN 2002:221971 USPATFULL
TI ENTEROCOCCUS FAECALIS POLYNUCLEOTIDES AND POLYPEPTIDES
IN KUNSCH, CHARLES A., ATLANTA, GA, UNITED STATES
DILLON, PATRICK J., CARLSBAD, CA, UNITED STATES
BARASH, STEVEN, ROCKVILLE, MD, UNITED STATES
PI US 2002120116 A1 20020829
AI US 1998-70927 A1 19980504 (9)
DT Utility
FS APPLICATION
LN.CNT 13315
INCL INCLM: 536/023.200
INCLS: 435/069.100; 435/070.100; 435/071.100; 435/252.300; 435/320.100; 530/350.000; 530/387.900; 800/013.000
NCL NCLM: 536/023.200
NCLS: 435/069.100; 435/070.100; 435/071.100; 435/252.300; 435/320.100; 530/350.000; 530/387.900; 800/013.000
IC [7]
ICM: C07K016-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 64 USPATFULL
AN 2002:149158 USPATFULL
TI USE OF HYALURONIC ACID AND FORMS TO PREVENT ARTERIAL RESTENOSIS
IN FALK, RUDOLF E., TORONTO, CANADA
ASCULAI, SAMUEL S., TORONTO, CANADA
TURLEY, EVA A., MANITOBA, CANADA
PI US 2002077314 A1 20020620
AI US 1997-996470 A1 19971222 (8)
RLI Continuation of Ser. No. US 1995-448503, filed on 26 Jul 1995, PATENTED Continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991, PATENTED Continuation-in-part of Ser. No. US 1992-838674, filed on 21 Feb 1992, ABANDONED Continuation-in-part of Ser. No. US 1992-838675, filed on 21 Feb 1992, PATENTED Continuation-in-part of Ser. No. US 1993-125398, filed on 23 Sep 1993, PATENTED
DT Utility
FS APPLICATION
LN.CNT 2015
INCL INCLM: 514/054.000
NCL NCLM: 514/054.000
IC [7]
ICM: A61K031-715
ICS: A01N043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 64 USPATFULL
AN 2002:126696 USPATFULL
TI METHODS AND COMPOSITIONS FOR NONVIRAL GENE DELIVERY
IN DEBS, ROBERT J., MILL VALLEY, CA, UNITED STATES
PI US 2002065213 A1 20020530
AI US 1999-232175 A1 19990115 (9)
PRAI US 1998-71598P 19980116 (60)
DT Utility
FS APPLICATION
LN.CNT 2940
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000; 514/044.000; 530/383.000; 435/069.100; 435/455.000; 435/352.000; 435/366.000
NCL NCLM: 514/002.000
NCLS: 514/008.000; 514/012.000; 514/044.000; 530/383.000; 435/069.100; 435/455.000; 435/352.000; 435/366.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17; C12P021-02; C12N005-06; C12N005-08; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 64 USPATFULL
AN 2002:105976 USPATFULL
TI Proteins involved in cytoadhesion of plasmodlum falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection
IN Gysin, Juerg, Saint Zacharie, FRANCE
Pouvelle, Bruno, Saint Maximin, FRANCE
Scherf, Artur, Paris, FRANCE
Buffet, Pierre, Paris, FRANCE
PA INSTITUT PASTEUR, Paris Cedex, FRANCE (non-U.S. corporation)
PI US 2002055183 A1 20020509
AI US 2001-867536 A1 20010531 (9)
PRAI US 2000-207952P 20000531 (60)
DT Utility
FS APPLICATION

LN.CNT 827
INCL INCLM: 436/512.000
NCL NCLM: 436/512.000
IC [7]
ICM: G01N033-563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 64 USPATFULL
AN 2002:84894 USPATFULL
TI Inhibition of intimal hyperplasia using antibodies to PDGF receptors
IN Hart, Charles E., Brier, WA, UNITED STATES
Kenagy, Richard D., Seattle, WA, UNITED STATES
Clowes, Alexander W., Seattle, WA, UNITED STATES
PI US 2002044933 A1 20020418
AI US 2001-950955 A1 20010912 (9)
RLI Continuation of Ser. No. US 1999-265116, filed on 9 Mar 1999, PENDING
Continuation of Ser. No. US 1995-482533, filed on 7 Jun 1995, GRANTED, Pat. No. US 5976534 Continuation-in-part of Ser. No. US 1994-366860, filed on 30 Dec 1994, GRANTED, Pat. No. US 5620687 Continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, ABANDONED Continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2979
INCL INCLM: 424/143.100
NCL NCLM: 424/143.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 64 USPATFULL
AN 2002:27460 USPATFULL
TI HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVETIONS
IN LASSILA, RIITTA, ESPOO, FINLAND
KOVANEN, PETRI, ESPOO, FINLAND
LINDSTEDT, KEN, HELSINKI, FINLAND
PI US 2002016308 A1 20020207
AI US 1999-230097 A1 19990120 (9)
WO 1998-FI925 19981125
PRAI FI 1997-4321 19971125
DT Utility
FS APPLICATION
LN.CNT 1964
INCL INCLM: 514/056.000
INCLS: 536/021.000; 536/124.000
NCL NCLM: 514/056.000
NCLS: 536/021.000; 536/124.000
IC [7]
ICM: A61K031-24
ICS: A61K031-715; C07H001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 64 USPATFULL
AN 2002:304070 USPATFULL
TI Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
IN Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Rochester, MN, United States
PA ARCH Development Corp., Chicago, IL, United States (U.S. corporation)
PI US 6482934 B1 20021119
AI US 2000-537226 20000328 (9)

RLI Continuation-in-part of Ser. No. US 1997-837226, filed on 10 Apr 1997, now patented, Pat. No. US 6043216 Continuation-in-part of Ser. No. US 1995-389005, filed on 15 Feb 1995, now patented, Pat. No. US 5618917
DT Utility
FS GRANTED
LN.CNT 2519
INCL INCLM: 536/023.100
INCLS: 536/023.100; 530/300.000; 530/350.000; 435/006.000; 435/069.100; 435/007.100; 435/320.100; 514/002.000; 514/008.000; 514/021.000
NCL NCLM: 536/023.100
NCLS: 536/023.100; 530/300.000; 530/350.000; 435/006.000; 435/069.100; 435/007.100; 435/320.100; 514/002.000; 514/008.000; 514/021.000
IC [7]
ICM: C07H021-02
EXF 536/23.1; 435/6; 435/69.1; 435/7.1; 435/320.1; 530/350; 530/300; 514/8; 514/2; 514/21

L12 ANSWER 16 OF 64 USPATFULL
AN 2002:275738 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6468529 B1 20021022
AI US 2000-669971 20000926 (9)
RLI Continuation of Ser. No. US 952235, now patented, Pat. No. US 6207152 Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995, now patented, Pat. No. US 5686292
DT Utility
FS GRANTED
LN.CNT 2994
INCL INCLM: 424/130.100
INCLS: 424/130.100; 424/133.100; 424/134.100; 424/135.100; 424/138.100; 424/141.100
NCL NCLM: 424/130.100
NCLS: 424/130.100; 424/133.100; 424/134.100; 424/135.100; 424/138.100; 424/141.100
IC [7]
ICM: A61K039-395
EXF 424/133.1; 424/134.1; 424/135.1; 424/138.1; 424/141.1; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 64 USPATFULL
AN 2002:217251 USPATFULL
TI Method for treating occlusive peripheral vascular disease and coronary disease
IN Barron, Hal V., San Francisco, CA, United States
Botvinick, Elias, San Rafael, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6440947 B1 20020827
AI US 1998-167816 19981007 (9)
RLI Continuation-in-part of Ser. No. US 1997-946196, filed on 7 Oct 1997
DT Utility
FS GRANTED
LN.CNT 1289
INCL INCLM: 514/046.000
INCLS: 514/046.000; 514/056.000; 514/059.000; 514/062.000
NCL NCLM: 514/046.000
NCLS: 514/056.000; 514/059.000; 514/062.000
IC [7]

ICM: A61K031-70
ICS: A01N043-04
EXF 514/46; 514/56; 514/59; 514/62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 18 OF 64 USPATFULL
AN 2002:152446 USPATFULL
TI Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
IN Samulski, Richard Jude, Chapel Hill, NC, United States
Summerford, Candace, Chapel Hill, NC, United States
PA The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States (U.S. corporation)
PI US 6410300 B1 20020625
AI US 1999-228203 19990111 (9)
PRAI US 1998-71210P 19980112 (60)
DT Utility
FS GRANTED
LN.CNT 2953
INCL INCLM: 435/239.000
INCLS: 435/235.100; 435/320.100; 435/005.000; 424/093.200
NCL NCLM: 435/239.000
NCLS: 424/093.200; 435/005.000; 435/235.100; 435/320.100
IC [7]
ICM: C12N007-00
ICS: C12N007-02
EXF 424/93.21; 424/93.2; 435/320.1; 435/5; 435/239; 435/325; 435/235.1; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 19 OF 64 USPATFULL
AN 2002:129536 USPATFULL
TI Chemokine--glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
IN Devico, Anthony L., Alexandria, VA, United States
Lewis, George K., Baltimore, MD, United States
Burns, Jennifer M., Baltimore, MD, United States
Gallo, Robert, Bethesda, MD, United States
PA University of Maryland Biotechnology Institute, Baltimore, MD, United States (U.S. corporation)
PI US 6399078 B1 20020604
AI US 1999-323719 19990601 (9)
PRAI US 1998-87436P 19980601 (60)
DT Utility
FS GRANTED
LN.CNT 2604
INCL INCLM: 424/278.100
INCLS: 424/185.100; 424/279.100; 514/002.000; 514/056.000; 514/059.000; 514/885.000
NCL NCLM: 424/278.100
NCLS: 424/185.100; 424/279.100; 514/002.000; 514/056.000; 514/059.000; 514/885.000
IC [7]
ICM: A61K047-00
ICS: A61K039-00; A61K045-00; A61K038-00; A61K031-727
EXF 514/2; 514/56; 514/59; 514/885; 424/278.1; 424/185.1; 424/279.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 20 OF 64 SCISEARCH COPYRIGHT 2002 ISI (R)
AN 2002:686324 SCISEARCH
GA The Genuine Article (R) Number: 582GX
TI Collagenase activity of cathepsin K depends on complex formation with

chondroitin sulfate
AU Li Z Q; Hou W S; Escalante-Torres C R; Gelb B D; Bromme D (Reprint)
CS Mt Sinai Sch Med, Dept Human Genet, Box 1498, 5th Ave 100 St, New York, NY 10029 USA (Reprint); Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (9 AUG 2002) Vol. 277, No. 32, pp. 28669-28676.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.
ISSN: 0021-9258.
DT Article; Journal
LA English
REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L12 ANSWER 21 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 4
AN 2002:403192 BIOSIS
DN PREV200200403192
TI Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration.
AU Christopherson, Kent W., II; Campbell, James J.; Travers, Jeffrey B.; Hromas, Robert A. (1)
CS (1) 1044 W. Walnut St., Indianapolis, IN, 46202: rhromas@iupui.edu USA
SO Journal of Pharmacology and Experimental Therapeutics, (July, 2002) Vol. 302, No. 1, pp. 290-295. http://jpet.aspetjournals.org. print.
ISSN: 0022-3565.
DT Article
LA English

L12 ANSWER 22 OF 64 IFIPAT COPYRIGHT 2002 IFI DUPLICATE 5
AN 10006631 IFIPAT;IFIUDB;IFICDB
TI USE OF HEPARINASE TO DECREASE INFLAMMATORY RESPONSES; DECREASING LOCALIZED INFLAMMATORY RESPONSES IN A TISSUE OF A PATIENT BY ADMINISTERING TO SAID PATIENT HEPARINASE ENZYME IN AN EFFECTIVE AMOUNT SUFFICIENT TO DECREASE SAID LOCALIZED INFLAMMATORY RESPONSE
IN BENNETT D CLARK (CA); CAUCHON ELIZABETH (CA); DANAGHER PAMELA (CA); FINK DOMINIQUE (CA); GROUIX BRIGETTE (CA); HSIA ARIANE (CA); ZIMMERMANN JOSEPH (CA)
PA Unassigned Or Assigned To Individual (68000)
PI US 2001006635 A1 20010705
AI US 1996-722659 19960927
FI US 2001006635 20010705
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 17
GI 19 Figure(s).
FIG. 1 is a graph of the counts of 35S-heparin/heparan sulfate released from the surface of endothelial cells by 1.0 IU/ml of **heparinase III**, which were separated according to size on a gel filtration column. The diamonds indicate counts released by a 5 minute digest, the squares indicate counts released by a 30 minute digest, and the triangles indicate counts released by a 60 minute digest. Background counts from fractionation of mock digests have been subtracted from the fractions derived from the **heparinase III** digests.
FIG. 2A and 2B are graphs of the percent of heparin/heparan sulfate present on the unactivated (2A) and IL-1b activated (2B) human endothelial cell line at the indicated times after treatment with 0.1 IU/ml heparinase I, II or III for 1 hour. 125I-bFGF binding to cell

surface heparin was used to determine the amount of heparin/heparan sulfate present. Results for heparinase I, II or III treated cells are indicated by diamonds, squares or triangles, respectively. The vertical lines indicate the standard error of the means.

FIG. 3A and 3B are graphs of the percent of heparin/heparan sulfate present on the unactivated (3A) and IL-1b activated (3B) human endothelial cell line at the indicated times after treatment with 1.0 IU/ml heparinase I. 125I-bFGF binding to cell surface heparin was used to determine the amount of heparin/heparan sulfate present. Results for 1, 3 or 5 hour treated cells are indicated by diamonds, squares or triangles, respectively. The vertical lines indicate the standard error of the means.

FIG. 4A and 4B are graphs of the percent of heparin/heparan sulfate present on the unactivated (4A) and IL-1b activated (4B) human endothelial cell line at the indicated times after treatment with 1.0 IU/ml **heparinase III**. 125I-bFGF binding to cell surface heparin was used to determine the amount of heparin/heparan sulfate present. Results for 1, 3 or 5 hour treated cells are indicated by diamonds, squares or triangles, respectively. The vertical lines indicate the standard error of the means.

FIG. 5 contains graphs displaying the levels of IL-8 released from IL-1b activated human endothelial cell layers by treatment with 1.0 IU/ml of heparinases; I (5A), II (5B), I+III (bars containing diagonal lines; 5B), and III (5C). The bars represent the percent difference in the concentration of IL-8 found in; supernatants from activated endothelial layers treated with heparinases, versus untreated supernatants from activated endothelial layers (containing only secreted IL-8). Standard errors for these percentage differences are indicated by vertical lines. The lines overlaid on the bars indicate the concentration of IL-8 in the supernatants from the heparinase treated cell layers. The standard errors of these measurements are also indicated by vertical lines (not always visible).

FIG. 6 is a graph of the level of neutrophil adhesion to endothelial cells, which were unactivated, IL-1b activated, or treated with 0.1 IU/ml of heparinases I, II or III after IL-1b activation. The level of adhesion is expressed as the percent of added neutrophils, which are adhering.

FIGS. 7A, 7B and 7C are graphs of the percent inhibition of neutrophil extravasation through IL-1b activated endothelial cell layers, which were treated with heparinases I, II or III, respectively. The bars containing diagonal lines represent results of one hour treatments with 1.0 IU/ml of heparinase. The white bars represent results of one hour treatments with 0. 1 IU/ml of heparinase. The black bars represent results of 15 minute treatments with 0.1 IU/ml of heparinase I or III, and the bar containing vertical lines represents results of 15 minute treatments with 1.0 IU/ml of heparinase II. The standard deviations for the percent inhibitions are indicated by vertical lines. The small asterisks indicate results of one hour treatments that were significantly different from the results of the 15 minute treatment with the same heparinase (P less-than 0.05). The large asterisks indicate the results of one hour treatments with 1.0 IU/ml of heparinase that were significantly different from the results of one hour treatments with 0.1 IU/ml of the same heparinase. The numbers in parentheses under the bars indicate the number of experiments included in each data set.

FIG. 8 is a graph showing the activity of human heparinase (bthromboglobulin) on ECM at pH 5.8 and 7. The solid bars represent the percent difference in 35SO4 released from ECM treated with 1 ug of human heparinase versus that released from untreated ECM. The bars containing diagonal lines represent the percent difference in 35SO4 released from ECM treated with 5 ug of human heparinase versus that released from untreated ECM. The standard deviation of the means are indicated by vertical lines.

FIG. 9 is a graph which displays the change in the level of neutrophil

extravasation upon activation of HUVEC layers with IL-1b, and after treatment of activated HUVEC layers with human heparinase (hhep). The standard deviation of the means are indicated by vertical lines.

FIG. 10 is a graph of rat plasma **heparinase III** concentrations over a five hour infusion period. Time points in the protocol are indicated by the arrows, with descriptions above the arrows. The vertical lines indicate the standard error of the means.

FIG. 11 is a graph of the level of leukocyte rolling in the rat microvasculature after 3 hours of ischemia, during reperfusion. The circles indicate the levels in naive rats, the squares indicate the levels in sham treated rats which underwent ischemia, and the triangles indicate the levels in heparinase treated rats which underwent ischemia. The vertical lines indicate the standard error of the means.

FIG. 12 is a graph of the level of leukocyte adhesion in the rat microvasculature after 3 hours of ischemia, during reperfusion. The circles indicate the levels in naive rats, the squares indicate the levels in sham treated rats which underwent ischemia, and the triangles indicate the levels in heparinase treated rats which underwent ischemia. The vertical lines indicate the standard error of the means.

FIG. 13 is a graph of the level of leukocyte extravasation in the rat microvasculature after 3 hours of ischemia, during reperfusion. The circles indicate the levels in heparinase treated rats which underwent ischemia. The vertical lines indicate the standard error of the means.

FIG. 14 is a graph of the level of leukocyte extravasation in the rat microvasculature after 2 hours of ischemia, during reperfusion. The open bars are the percent difference in the levels in sham treated rats versus the levels in naive rats. The bars containing diagonal lines are the percent difference in the levels in heparinase treated rats versus the levels in naive rats. The vertical lines indicate the standard error of the means.

FIG. 15 is a graph of the level of perfusion in rat postcapillary venules after 3 hours of ischemia, during reperfusion. The circles indicate the levels in naive rats, the squares indicate the levels in sham treated rats which underwent ischemia, and the triangles indicate the levels in heparinase treated rats which underwent ischemia. The vertical lines indicate the standard error of the means.

FIG. 16 is a graph of the heart rate-blood pressure product for rabbits during ischemia and reperfusion with or without heparinase treatment. The open circles and squares are data for saline pretreated and reperfusion treated rats, respectively. The open pyramids and solid circles are data for heparinase pretreated and reperfusion treated rabbits, respectively (25 ug/ ml **target** plasma levels for **heparinase III**). The solid squares, pyramids and diamonds are data for heparinase reperfusion treated rabbits with 5, 1.25 and 0.25 ug/ml **target** plasma levels of **heparinase III**, respectively. BASE indicates baseline levels. 30I indicates the level at 30 minutes of ischemia. 30R, 60R, 120R and 180R indicates the levels at 30, 60 120 and 180 minutes of reperfusion. The vertical lines indicate the standard deviation of the means.

FIG. 17 is a graph of the percent of the infarct size vs. risk zone after ischemia and reperfusion in rabbit hearts, which underwent different heparinase treatments. The solid circles indicate the average levels for each treatment group. The open shapes indicate the levels for individual rabbits. CPT and CRT indicate saline pretreated and reperfusion treated rabbits, respectively. DPT and DRT indicate heparinase pretreated and reperfusion treated rabbits, respectively. The numbers below DPT and DRT indicate the **target** level of **heparinase III** in the plasma (in ug/ml). The vertical lines indicate the standard deviation of the means.

FIG. 18 is a graph of the concentration of **heparinase III** which was infused into the heparinase treated rabbits (in IU/ml). DPT and DRT indicate heparinase pretreated and reperfusion

treated rabbits, respectively. The numbers below DPT and DRT indicate the **target** level of **heparinase III** in the plasma (in ug/ml). Con indicates control rabbits infused with saline. The vertical lines indicate the standard deviation of the means.

FIG. 19 is a graph of the concentrations of **heparinase III** measured in the rabbit plasma during pretreatment and reperfusion. The circles indicate the actual concentrations measured in heparinase pretreated rabbits targeted for 25 ug/ml plasma concentrations of **heparinase III**. The squares, pyramids, triangles and diamonds indicate the actual concentrations measured in heparinase reperfusion treated rabbits targeted for 25, 5, 1.25 and 0.25 ug/ml plasma concentrations of **heparinase III**, respectively. BASE indicates baseline concentrations. 30P and 60P indicate concentrations at 30 and 60 minutes of pretreatment. 15R, 30R, 60R, 120R and 180R indicate concentrations at 15, 30, 60 120 and 180 minutes of reperfusion, respectively. The vertical lines indicate the standard deviation of the means.

L12 ANSWER 23 OF 64 USPATFULL DUPLICATE 6
AN 2001:165448 USPATFULL
TI Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
IN Chen, Feng-Jing, Salt Lake City, UT, United States
Patel, Mahesh V., Salt Lake City, UT, United States
Fikstad, David T., Salt Lake City, UT, United States
PI US 2001024658 A1 20010927
US 6458383 B2 20021001
AI US 2000-751968 A1 20001229 (9)
RLI Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, PENDING
PRAI WO 2000-US18807 20000710
DT Utility
FS APPLICATION
LN.CNT 2150
INCL INCLM: 424/452.000
INCLS: 514/056.000; 514/171.000
NCL NCLM: 424/451.000
NCLS: 424/450.000; 424/451.000; 424/455.000; 424/456.000; 424/463.000; 424/489.000; 424/499.000; 424/502.000; 424/435.000; 424/464.000; 424/434.000; 514/937.000; 514/938.000; 514/939.000; 514/940.000; 514/941.000; 514/942.000; 514/943.000; 514/975.000; 514/056.000
IC [7]
ICM: A61K031-727
ICS: A61K009-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 24 OF 64 USPATFULL
AN 2001:163029 USPATFULL
TI Human basic fibroblast growth factor analog
IN Fiddes, John C., Palo Alto, CA, United States
Abraham, Judith A., Sunnyvale, CA, United States
Protter, Andrew, Palo Alto, CA, United States
PA Scios Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6294359 B1 20010925
AI US 1998-98628 19980616 (9)
RLI Division of Ser. No. US 1990-459739, filed on 12 Feb 1990, now patented, Pat. No. US 5859208 Continuation-in-part of Ser. No. US 1987-70797, filed on 7 Jul 1987, now abandoned Continuation-in-part of Ser. No. US 1987-50706, filed on 15 May 1987, now abandoned Continuation-in-part of Ser. No. US 1986-869382, filed on 30 May 1986, now abandoned Continuation-in-part of Ser. No. US 1985-809163, filed on 16 Dec 1985, now patented, Pat. No. US 5439818 Continuation-in-part of Ser. No. US

1985-775521, filed on 12 Sep 1985, now abandoned
DT Utility
FS GRANTED
LN.CNT 2374
INCL INCLM: 435/069.400
INCLS: 435/243.000; 435/320.100; 435/325.000; 530/399.000
NCL NCLM: 435/069.400
NCLS: 435/243.000; 435/320.100; 435/325.000; 530/399.000
IC [7]
ICM: C12N015-18
ICS: C12N015-63; C12N001-21; C12N005-16; C07K014-50
EXF 435/69.4; 435/320.1; 435/325; 435/243; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 25 OF 64 USPATFULL
AN 2001:43710 USPATFULL
TI Hepatocyte growth factor receptor antagonists and uses thereof
IN Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 6207152 B1 20010327
WO 9638557 19961205
AI US 1998-952235 19980217 (8)
WO 1996-US8094 19960531
19980217 PCT 371 date
19980217 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-460368, filed on 2 Jun 1995, now patented, Pat. No. US 5686292
DT Utility
FS Granted
LN.CNT 2855
INCL INCLM: 424/130.100
INCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/156.100; 424/174.100; 530/387.100; 530/387.300; 530/388.220; 530/388.880; 530/388.850; 530/389.100; 530/389.700; 435/007.100; 435/007.200; 435/007.210; 435/007.230
NCL NCLM: 424/130.100
NCLS: 424/133.100; 424/138.100; 424/141.100; 424/143.100; 424/152.100; 424/155.100; 424/156.100; 424/174.100; 435/007.100; 435/007.200; 435/007.210; 435/007.230; 530/387.100; 530/387.300; 530/388.220; 530/388.800; 530/388.850; 530/389.100; 530/389.700
IC [7]
ICM: C07K016-18
ICS: C07K016-28; A61K039-395
EXF 530/388.22; 530/387.1; 530/387.3; 530/388.88; 530/388.85; 530/389.1; 530/389.7; 424/130.1; 424/133.1; 424/138.1; 424/141.1; 424/143.1; 424/152.1; 424/155.1; 424/156.1; 424/174.1; 435/7.1; 435/7.2; 435/7.21; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 26 OF 64 USPATFULL
AN 2001:33065 USPATFULL
TI Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms
IN Marks, Rory M., Ann Arbor, MI, United States
Chen, Yaping, San Diego, CA, United States
Maguire, Terence, Waverly Dunedin, New Zealand
Linhardt, Robert J., Iowa City, IA, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
PI US 6197568 B1 20010306
AI US 1998-123770 19980728 (9)

PRAI US 1997-53828P 19970729 (60)
DT Utility
FS Granted
LN.CNT 1449
INCL INCLM: 435/239.000
INCLS: 435/005.000; 435/007.100; 435/007.800; 435/029.000; 435/803.000; 435/948.000; 424/185.000; 424/193.100; 424/196.110; 424/197.110; 424/279.100; 514/023.000; 514/054.000; 514/055.000; 514/056.000; 514/057.000; 514/058.000; 514/059.000; 514/060.000; 514/061.000; 514/062.000
NCL NCLM: 435/239.000
NCLS: 424/185.100; 424/193.100; 424/196.110; 424/197.110; 424/279.100; 435/005.000; 435/007.100; 435/007.800; 435/029.000; 435/803.000; 435/948.000; 514/023.000; 514/054.000; 514/055.000; 514/056.000; 514/057.000; 514/058.000; 514/059.000; 514/060.000; 514/061.000; 514/062.000
IC [7]
ICM: C12Q001-70
ICS: A61K039-29; A61K031-70; A01N043-04; C12N007-02
EXF 435/7.1; 435/5; 435/7.8; 435/29; 435/239; 435/803; 435/948; 424/185.1; 424/196.11; 424/197.11; 424/193.1; 424/279.1; 514/23; 514/54-62
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 27 OF 64 USPATFULL
AN 2001:29322 USPATFULL
TI Enhanced expression of human platelet-derived growth factor in Pichia pastoris
IN Kaetzel, David M., Georgetown, KY, United States
PA The University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)
PI US 6194169 B1 20010227
AI US 1998-90381 19980604 (9)
DT Utility
FS Granted
LN.CNT 792
INCL INCLM: 435/069.100
INCLS: 435/069.400; 435/070.100; 435/071.100; 435/254.200; 435/254.230; 435/255.100; 435/255.500; 435/252.300; 435/069.800; 435/471.000; 435/320.100; 435/483.000; 435/325.000; 435/360.000; 435/366.000
NCL NCLM: 435/069.100
NCLS: 435/069.400; 435/069.800; 435/070.100; 435/071.100; 435/252.300; 435/254.200; 435/254.230; 435/255.100; 435/255.500; 435/320.100; 435/325.000; 435/360.000; 435/366.000; 435/471.000; 435/483.000
IC [7]
ICM: C12N015-09
ICS: C12N015-63; C12N001-16; C12N005-10; C12P021-02
EXF 435/69.1; 435/69.4; 435/70.1; 435/71.1; 435/254.2; 435/254.23; 435/255.1; 435/255.5; 435/252.3; 435/69.8; 435/471; 435/320.1; 435/483; 435/325; 435/360; 435/366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 28 OF 64 WPINDEX (C) 2002 THOMSON DERWENT
AN 2001-596840 [67] WPINDEX
DNC C2001-176618
TI Novel modified **heparinase III** polypeptides useful for treating cancer and inhibiting tumor cell growth and/or metastasis, sequencing **heparin-like glycosaminoglycans**, and removing active heparan sulfate from solution.
DC B04 D16
IN EL-SHABRAWI, Y; HOLLEY, K; LIU, D; POJASEK, K; SASISEKHARAN, R; SHRIVER, Z; VENKATARAMAN, G; DONGFANG, L
PA (MASI) MASSACHUSETTS INST TECHNOLOGY; (ELSH-I) EL-SHABRAWI Y; (HOLL-I)

HOLLEY K; (LIUD-I) LIU D; (POJA-I) POJASEK K; (SASI-I) SASISEKHARAN R; (SHRI-I) SHRIVER Z; (VENK-I) VENKATARAMAN G
CYC 23
PI WO 2001066772 A2 20010913 (200167)* EN 94p C12N015-60
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
W: AU CA JP
AU 2001043512 A 20010917 (200204) C12N015-60
US 2002122793 A1 20020905 (200260) A61K038-47
ADT WO 2001066772 A2 WO 2001-US7464 20010308; AU 2001043512 A AU 2001-43512 20010308; US 2002122793 A1 Provisional US 2000-187846P 20000308, US 2001-802285 20010308
FDT AU 2001043512 A Based on WO 200166772
PRAI US 2000-187846P 20000308; US 2001-802285 20010308
IC ICM A61K038-47; C12N015-60
ICS A61K031-715; A61K038-51; C08B037-00; C12N009-24; C12N009-88

L12 ANSWER 29 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 7
AN 2001:235119 BIOSIS
DN PREV200100235119
TI Human herpesvirus 8 interaction with **target** cells involves heparan sulfate.
AU Akula, Shaw M.; Wang, Fu-Zhang; Vieira, Jeffrey; Chandran, Bala (1)
CS (1) Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS, 66160-7424: bchandra@kumc.edu USA
SO Virology, (April 10, 2001) Vol. 282, No. 2, pp. 245-255. print.
ISSN: 0042-6822.
DT Article
LA English
SL English

L12 ANSWER 30 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:254610 BIOSIS
DN PREV200100254610
TI Proteoglycans regulate pulmonary fibroblast cellular response and extracellular matrix composition.
AU Buczek-Thomas, Jo Ann (1); Rich, Celeste B. (1); Stone, Phillip J. (1); Foster, Judith A. (1); Nugent, Matthew A. (1)
CS (1) Boston University School of Medicine, 80 East Concord Street, Boston, MA, 02118 USA
SO FASEB Journal, (March 7, 2001) Vol. 15, No. 4, pp. A244. print.
Meeting Info.: Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638.
DT Conference
LA English
SL English

L12 ANSWER 31 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:163555 BIOSIS
DN PREV200200163555
TI Low molecular weight heparins inhibit CCL21-induced T-cell migration: **Targeting** the endothelial expression of CCL21 in autoimmune diseases.
AU Christopherson, Kent W. (1); Campbell, James J.; Travers, Jeffrey B.; Hood, Antoinette F.; Ramsey, Heather C. (1); Hromas, Robert A. (1)
CS (1) Departments of Biochemistry/Molecular Biology, Hematology/Oncology, Walther Oncology Center, Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, IN USA
SO Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 233a.

http://www.bloodjournal.org/. print.
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971.
DT Conference
LA English

L12 ANSWER 32 OF 64 USPATFULL
AN 2000:160585 USPATFULL
TI Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
IN Yacoby-Zeevi, Oron, Meitar, Israel
PA Insight Strategy & Marketing Ltd., Rohouot, Israel (non-U.S. corporation)
PI US 6153187 20001128
AI US 1998-46475 19980325 (9)
RLI Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, now patented, Pat. No. US 5968822
DT Utility
FS Granted
LN.CNT 1041
INCL INCLM: 424/094.500
INCLS: 424/094.610; 424/094.620; 424/094.600; 435/232.000
NCL NCLM: 424/094.500
NCLS: 424/094.600; 424/094.610; 424/094.620; 435/232.000
IC [7]
ICM: A61K038-51
ICS: C12N009-88
EXF 424/94.5; 424/94.61; 424/94.62; 424/94.6; 435/232
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 33 OF 64 USPATFULL
AN 2000:101874 USPATFULL
TI Hepatocyte growth factor receptor agonists and uses thereof
IN Hillan, Kenneth J., San Francisco, CA, United States
Schwall, Ralph H., Pacifica, CA, United States
Tabor, Kelly H., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6099841 20000808
AI US 1997-884669 19970627 (8)
PRAI US 1996-21215P 19960703 (60)
DT Utility
FS Granted
LN.CNT 1908
INCL INCLM: 424/143.100
INCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000; 530/387.700; 530/387.300; 530/388.220; 530/389.100; 530/389.200; 530/389.700; 530/350.000
NCL NCLM: 424/143.100
NCLS: 424/134.100; 424/135.100; 424/136.100; 424/138.100; 435/334.000; 530/350.000; 530/387.300; 530/387.700; 530/388.220; 530/389.100; 530/389.200; 530/389.700
IC [7]
ICM: C07K016-28
ICS: C12N015-06; A61K039-395
EXF 530/388.22; 530/389.1; 530/387.3; 530/350; 530/387.7; 530/389.7; 530/389.2; 435/334; 435/7.1; 514/2; 424/143.1; 424/134.1; 424/135.1; 424/136.1; 424/138.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 34 OF 64 USPATFULL.

AN 2000:98391 USPATFULL
TI Growth-promoting proteins and peptides for kidney epithelial cells
IN Toback, F. Gary, Chicago, IL, United States
Walsh-Reitz, Margaret M., River Forest, IL, United States
PA Arch Development Corporation, Chicago, IL, United States (U.S. corporation)
PI US 6096706 20000801
AI US 1997-974775 19971120 (8)
DT Utility
FS Granted
LN.CNT 2210
INCL INCLM: 514/002.000
INCLS: 514/016.000; 514/015.000; 514/014.000; 514/013.000; 530/300.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000
NCL NCLM: 514/002.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/300.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000
IC [7]
ICM: C07K007-06
ICS: C07K007-08; A61K038-08; A61K038-16
EXF 514/2; 514/12-17; 530/300; 530/326-329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 35 OF 64 USPATFULL
AN 2000:37772 USPATFULL
TI Methods and composition for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
IN Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Evanston, IL, United States
PA Arch Development Corporation, Chicago, IL, United States (U.S. corporation)
PI US 6043216 20000328
AI US 1997-837226 19970410 (8)
RLI Continuation-in-part of Ser. No. US 1995-389005, filed on 15 Feb 1995, now patented, Pat. No. US 5618917, issued on 8 Apr 1997
DT Utility
FS Granted
LN.CNT 2531
INCL INCLM: 514/008.000
INCLS: 530/395.000; 530/412.000; 530/425.000; 530/835.000
NCL NCLM: 514/008.000
NCLS: 530/395.000; 530/412.000; 530/425.000; 530/835.000
IC [7]
ICM: A61K038-17
ICS: C07K001-14; C07K014-47
EXF 436/501; 436/503; 436/87; 436/811; 514/8; 514/12; 514/21; 530/395; 530/412; 530/425; 530/834; 530/835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 36 OF 64 USPATFULL
AN 2000:15642 USPATFULL
TI Use of hyaluronic acid and forms to prevent arterial restenosis
IN Falk, Rudolf Edgar, Toronto, Canada
Asculai, Samuel Simon, Toronto, Canada
Turley, Eva Anne, Winnipeg, Canada
PA Hyal Pharmaceutical Corporation, Mississauga, Canada (non-U.S. corporation)
PI US 6022866 20000208
WO 9407505 19940414
AI US 1995-403766 19950324 (8)
WO 1993-CA388 19930922
19950324 PCT 371 date

19950324 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-285764, filed on 3 Aug 1994, now patented, Pat. No. US 5614506, issued on 25 Mar 1997 which is a continuation-in-part of Ser. No. US 1992-952095, filed on 28 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991 And Ser. No. US 1992-838675, filed on 21 Feb 1992, now patented, Pat. No. US 5639738, issued on 17 Jun 1997
PRAI CA 1992-2079205 19920925
DT Utility
FS Granted
LN.CNT 1554
INCL INCLM: 514/054.000
INCLS: 514/023.000; 514/025.000; 514/028.000; 514/032.000; 514/042.000; 514/056.000; 514/060.000; 514/062.000; 536/055.000
NCL NCLM: 514/054.000
NCLS: 514/023.000; 514/025.000; 514/028.000; 514/032.000; 514/042.000; 514/056.000; 514/060.000; 514/062.000; 536/055.000
IC [6]
ICM: A61K031-70
EXF 424/180; 514/23; 514/25; 514/28; 514/32; 514/33; 514/42; 514/54; 514/56; 514/60; 514/62; 536/55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 37 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 8
AN 2000:292364 BIOSIS
DN PREV200000292364
TI Attenuation of wound healing processes.
AU Zimmermann, Joseph (1); Vlodavsky, Israel; Bennett, Clark; Danagher, Pamel; Broughton, Richard
CS (1) Montreal Canada
ASSIGNEE: Ibex Technologies R and D, Inc., Montreal, Canada
PI US 5997863 December 07, 1999
SO Official Gazette of the United States Patent and Trademark Office Patents, (Dec. 7, 1999) Vol. 1229, No. 1, pp. No pagination. e-file.
ISSN: 0098-1133.
DT Patent
LA English

L12 ANSWER 38 OF 64 USPATFULL
AN 1999:151198 USPATFULL
TI Use of hyaluronic acid and forms to prevent arterial restenosis
IN Falk, Rudolf Edgar, Toronto, Canada
Ascuali, Samuel Simon, Toronto, Canada
Turley, Eva Anne, Winnipeg, Canada
PA Hyal Pharmaceutical Corporation, Mississauga, Canada (non-U.S. corporation)
PI US 5990095 19991123
AI US 1995-448503 19950726 (8)
WO 1994-CA188 19940325
19950726 PCT 371 date
19950726 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1991-675908, filed on 3 Jul 1991 And a continuation-in-part of Ser. No. US 1992-838674, filed on 21 Feb 1992, now abandoned Ser. No. Ser. No. US 1992-838675, filed on 21 Feb 1992, now patented, Pat. No. US 5639738 Ser. No. Ser. No. US 1992-952095, filed on 28 Sep 1992, now abandoned And Ser. No. US 1993-125398, filed on 23 Sep 1993, now patented, Pat. No. US 5834444
DT Utility
FS Granted
LN.CNT 1906
INCL INCLM: 514/054.000

NCL NCLM: 514/054.000
IC [6]
ICM: A61K031-70
EXF 536/55.1; 536/55.2; 514/54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 39 OF 64 USPATFULL
AN 1999:136684 USPATFULL
TI Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
IN Hart, Charles E., Brier, WA, United States
Kenagy, Richard D., Seattle, WA, United States
Clowes, Alexander W., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5976534 19991102
AI US 1995-482533 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-366860, filed on 30 Dec 1994, now patented, Pat. No. US 5620687 which is a continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2864
INCL INCLM: 424/145.100
INCLS: 424/130.100; 424/133.100; 424/135.100; 424/141.100; 424/158.100; 514/056.000
NCL NCLM: 424/145.100
NCLS: 424/130.100; 424/133.100; 424/135.100; 424/141.100; 424/158.100; 514/056.000
IC [6]
ICM: A61K039-395
ICS: A61K031-725
EXF 424/130.1; 424/133.1; 424/135.1; 424/141.1; 424/143.1; 424/158.1; 514/56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 40 OF 64 USPATFULL
AN 1999:132605 USPATFULL
TI Method and kit for detecting heparin induced thrombocytopenia
IN Aster, Richard H., Milwaukee, WI, United States
Visentin, Gian, Shorewood, WI, United States
PA The Blood Center Research Foundation, Inc., Milwaukee, WI, United States (U.S. corporation)
PI US 5972717 19991026
AI US 1997-974331 19971119 (8)
RLI Continuation of Ser. No. US 1995-438470, filed on 10 May 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1265
INCL INCLM: 436/503.000
INCLS: 427/002.130; 435/007.100; 435/007.200; 435/007.900; 435/007.920; 435/007.940; 435/013.000; 435/028.000; 435/961.000; 435/970.000; 435/975.000; 436/501.000; 436/503.000; 436/513.000; 436/518.000; 436/529.000; 436/174.000; 436/175.000; 436/176.000; 436/530.000; 436/531.000; 436/532.000; 436/808.000
NCL NCLM: 436/503.000
NCLS: 427/002.130; 435/007.100; 435/007.200; 435/007.900; 435/007.920; 435/007.940; 435/013.000; 435/028.000; 435/961.000; 435/970.000; 435/975.000; 436/174.000; 436/175.000; 436/176.000; 436/501.000; 436/513.000; 436/518.000; 436/529.000; 436/530.000; 436/531.000; 436/532.000; 436/808.000

IC [6]
ICM: C12Q001-56
ICS: C12Q001-28; G01N033-53; G01N033-563
EXF 427/2.13; 435/7.1; 435/7.2; 435/7.94; 435/13; 435/28; 435/961; 435/970; 435/975; 435/7.9; 435/7.92; 436/501; 436/503; 436/513; 436/518; 436/529; 436/174; 436/175; 436/176; 436/530; 436/531; 436/532; 436/808; 436/811; 436/825; 514/54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 41 OF 64 USPATFULL
AN 1999:75550 USPATFULL
TI Nucleic acid sequences and expression systems for heparinase II and **heparinase III** derived from Flavobacterium heparinum
IN Su, Hongsheng, Lonqnenil, Canada
Blain, Francoise, Que, Canada
Bennett, Clark, Quebec, Canada
Gu, Kangfu, Quebec, Canada
Zimmermann, Joseph, Elm Grove, WI, United States
Musil, Roy, Carlsbad, CA, United States
PA IBEX Technologies Corp., Malvern, PA, United States (U.S. corporation)
PI US 5919693 19990706
AI US 1997-900951 19970725 (8)
RLI Division of Ser. No. US 1994-258639, filed on 10 Jun 1994, now patented, Pat. No. US 5681733
DT Utility
FS Granted
LN.CNT 1605
INCL INCLM: 435/252.300
INCLS: 536/023.200; 536/024.100; 435/320.100; 435/252.330; 435/232.000
NCL NCLM: 435/252.300
NCLS: 435/232.000; 435/252.330; 435/320.100; 536/023.200; 536/024.100
IC [6]
ICM: C12N015-60
ICS: C12N001-21; C12N015-63; C12N009-88
EXF 536/23.2; 536/24.1; 435/320.1; 435/252.3; 435/252.33; 435/232
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 42 OF 64 USPATFULL
AN 1999:4861 USPATFULL
TI Human basic fibroblast growth factor analog
IN Fiddes, John C., 2320 Bryant St., Palo Alto, CA, United States 94301
Abraham, Judith A., 655 S. Fairoaks Ave., Sunnyvale, CA, United States 94086
Protter, Andrew A., 185 N. California Ave., Palo Alto, CA, United States 94301
PI US 5859208 19990112
WO 8900198 19890112
AI US 1990-459739 19900212 (7)
WO 1988-US2264 19880706
19900212 PCT 371 date
19900212 PCT 102(e) date
DT Utility
FS Granted
LN.CNT 2048
INCL INCLM: 530/399.000
INCLS: 530/350.000
NCL NCLM: 530/399.000
NCLS: 530/350.000
IC [6]
ICM: C07K014-50
EXF 530/399; 530/350; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 43 OF 64 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 1999275527 EMBASE
TI Plasmodium falciparum: Molecular background to strain-specific rosette disruption by glycosaminoglycans and sulfated glycoconjugates.
AU Barragan A.; Spillmann D.; Kremsner P.G.; Wahlgren M.; Carlson J.
CS J. Carlson, Microbiol. and Tumor Biology Center, Karolinska Institutet, Swedish Inst. for Infect. Dis. Ctrl., S-171 77 Stockholm, Sweden. johan.carlson@smi.ki.se
SO Experimental Parasitology, (1999) 91/2 (133-143).
Refs: 41
ISSN: 0014-4894 CODEN: EXPAAA
CY United States
DT Journal; Article
FS 004 Microbiology
037 Drug Literature Index
LA English
SL English

L12 ANSWER 44 OF 64 USPATFULL
AN 1998:127903 USPATFULL
TI Modulation of endothelial cell proliferation with IP-10
IN Luster, Andrew, Wellesley, MA, United States
Leder, Philip, Chestnut Hill, MA, United States
PA President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5824299 19981020
AI US 1995-493638 19950622 (8)
DT Utility
FS Granted
LN.CNT 1553
INCL INCLM: 424/085.100
INCLS: 514/002.000
NCL NCLM: 424/085.100
NCLS: 514/002.000
IC [6]
ICM: A61K038-19
ICS: A61K038-16
EXF 514/2; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 45 OF 64 CAPLUS COPYRIGHT 2002 ACS
AN 1997:303407 CAPLUS
DN 126:272357
TI Use of heparinases to decrease inflammatory responses
IN Bennett, D. Clark; Cauchon, Elizabeth; Fink, Dominique; Grouix, Brigette; Hsia, Ariane; Danagher, Pamela; Zimmerman, Joseph
PA Ibex Technologies Inc., Can.; Bennett, D. Clark; Cauchon, Elizabeth; Fink, Dominique; Grouix, Brigette; Hsia, Ariane; Danagher, Pamela; Zimmerman, Joseph
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9711684	A1	19970403	WO 1996-US15593	19960927
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, SG, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2233343	AA	19970403	CA 1996-2233343	19960927

	AU 9673791	A1	19970417	AU 1996-73791	19960927
	AU 703394	B2	19990325		
	EP 852491	A1	19980715	EP 1996-936052	19960927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11512721	T2	19991102	JP 1996-513723	19960927
	US 2001006635	A1	20010705	US 1996-722659	19960927
PRAI	US 1995-4622P	P	19950929		
	WO 1996-US15593	W	19960927		

L12 ANSWER 46 OF 64 USPATFULL
AN 97:99186 USPATFULL
TI Nucleic acid sequences and expression systems for heparinase II and **heparinase III** derived from Flavobacterium heparinum
IN Su, Hongsheng, Longueuil, Canada
Blain, Francoise, Mtl., Canada
Bennett, Clark, Pierrefonds, Canada
Gu, Kangfu, D.D.O., Canada
Zimmermann, Joseph, Elm Grove, WI, United States
Musil, Roy, Carlsbad, CA, United States
PA Ibex Technologies, Montreal, Canada (non-U.S. corporation)
PI US 5681733 19971028
AI US 1994-258639 19940610 (8)
DT Utility
FS Granted
LN.CNT 1467
INCL INCLM: 435/232.000
INCLS: 536/023.200
NCL NCLM: 435/232.000
NCLS: 536/023.200
IC [6]
ICM: C12N009-88
ICS: C12N015-60
EXF 435/232; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 47 OF 64 USPATFULL
AN 97:44760 USPATFULL
TI Antibodies specific for E-selectin and the uses thereof
IN Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Brigham & Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5632991 19970527
AI US 1994-365470 19941229 (8)
RLI Continuation-in-part of Ser. No. US 1993-102510, filed on 5 Aug 1993, now patented, Pat. No. US 5403713 which is a continuation of Ser. No. US 1992-850802, filed on 13 Mar 1992, now abandoned which is a division of Ser. No. US 1988-270860, filed on 14 Nov 1988, now abandoned
DT Utility
FS Granted
LN.CNT 2191
INCL INCLM: 424/178.100
INCLS: 424/143.100; 424/172.100; 530/395.000; 530/391.700
NCL NCLM: 424/178.100
NCLS: 424/143.100; 424/172.100; 530/391.700; 530/395.000
IC [6]
ICM: A61K039-395
ICS: A61K039-44; C07K016-28
EXF 424/152.1; 424/172.1; 424/178.1; 424/143.1; 530/388.22; 530/389.1; 530/391.1; 530/391.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 48 OF 64 USPATFULL

AN 97:31409 USPATFULL
TI Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
IN Hart, Charles E., Brier, WA, United States
Kenagy, Richard D., Seattle, WA, United States
Clowes, Alexander W., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 5620687 19970415
AI US 1994-366860 19941230 (8)
RLI Continuation-in-part of Ser. No. US 1994-304623, filed on 12 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-23504, filed on 25 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2786
INCL INCLM: 424/143.100
INCLS: 424/130.100; 424/133.100; 424/135.100; 424/152.100
NCL NCLM: 424/143.100
NCLS: 424/130.100; 424/133.100; 424/135.100; 424/152.100
IC [6]
ICM: A61K039-395
EXF 424/130.1; 424/133.1; 424/135.1; 424/136.1; 424/141.1; 424/143.1; 424/145.1; 424/156.1; 424/152.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 49 OF 64 USPATFULL
AN 97:29572 USPATFULL
TI Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
IN Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Evanston, IL, United States
PA ARCH Development Corporation, Chicago, IL, United States (U.S. corporation)
PI US 5618917 19970408
AI US 1995-389005 19950215 (8)
DT Utility
FS Granted
LN.CNT 1623
INCL INCLM: 530/350.000
INCLS: 434/558.000
NCL NCLM: 530/350.000
NCLS: 424/558.000
IC [6]
ICM: C07K014-435
ICS: A01K038-17
EXF 530/350; 514/2; 424/558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 50 OF 64 AGRICOLA DUPLICATE 9
AN 97:53785 AGRICOLA
DN IND20580794
TI Host cell heparan sulfate proteoglycans mediate attachment and entry of Listeria monocytogenes, and the listerial surface protein ActA is involved in heparan sulfate receptor recognition.
AU Alvarez-Dominguez, C.; Vazquez-Boland, J.A.; Carrasco-Marin, E.; Lopez-Mato, P.; Leyva-Cobian, F.
CS Washington University School of Medicine, St. Louis, Mo.
SO Infection and immunity, Jan 1997. Vol. 65, No. 1. p. 78-88
Publisher: Washington, D.C., American Society for Microbiology
ISSN: 0019-9567
NTE Includes references

CY District of Columbia; United States
DT Article
FS U.S. Imprints not USDA, Experiment or Extension
LA English

L12 ANSWER 51 OF 64 CAPLUS COPYRIGHT 2002 ACS
AN 1996:237498 CAPLUS
DN 124:250963
TI Glycosaminoglycan-degrading enzymes for modulation of wound healing processes
IN Zimmermann, Joseph; Vlodavsky, Israel; Bennett, D. Clark; Danagher, Pamela; Broughton, Richard
PA Ibex Technologies R and D, Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9601648	A1	19960125	WO 1995-US8608	19950707
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5997863	A	19991207	US 1994-273109	19940708
	CA 2194370	AA	19960125	CA 1995-2194370	19950707
	AU 9530949	A1	19960209	AU 1995-30949	19950707
	AU 707007	B2	19990701		
	EP 769961	A1	19970502	EP 1995-926645	19950707
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10506609	T2	19980630	JP 1995-504443	19950707
PRAI	US 1994-273109		19940708		
	WO 1995-US8608		19950707		

L12 ANSWER 52 OF 64 USPATFULL
AN 96:96761 USPATFULL
TI Method for inhibiting angiogenesis using heparinase
IN Sasisekharan, Ramnath, Arlington, MA, United States
Moses, Marsha A., Brookline, MA, United States
Nugent, Matthew A., Bedford, MA, United States
Cooney, Charles L., Brookline, MA, United States
Langer, Robert S., Newton, MA, United States
PA Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5567417 19961022
AI US 1995-431476 19950501 (8)
RLI Continuation of Ser. No. US 1993-153873, filed on 17 Nov 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1147
INCL INCLM: 424/094.500
INCLS: 435/232.000
NCL NCLM: 424/094.500
NCLS: 435/232.000
IC [6]
ICM: A61K038-51
EXF 424/94.5; 435/232

L12 ANSWER 53 OF 64 USPATFULL
AN 96:55855 USPATFULL

TI Methods for purification of recombinantly produced proteins
IN Darling, Thomas L. J., Lafayette Hill, PA, United States
Akhnana, Lida Y., Audubon, PA, United States
Mitschelen, Jonathan J., Perkiomenville, PA, United States
Hrinda, Michael E., Gwynedd Valley, PA, United States
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)
PI US 5530100 19960625
AI US 1990-519709 19900507 (7)
DT Utility
FS Granted
LN.CNT 1475
INCL INCLM: 530/383.000
INCLS: 435/069.600; 530/408.000; 530/410.000; 530/417.000; 530/422.000; 530/423.000; 530/424.000; 530/427.000
NCL NCLM: 530/383.000
NCLS: 435/069.600; 530/408.000; 530/410.000; 530/417.000; 530/422.000; 530/423.000; 530/424.000; 530/425.000; 530/427.000
IC [6]
ICM: C07K003-08
ICS: C07K003-12; C07K003-20; C07K015-06
EXF 530/383; 530/408; 530/410; 530/427; 530/415; 530/417; 530/422; 530/423; 530/424; 530/425; 435/69.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 54 OF 64 USPATFULL
AN 96:7785 USPATFULL
TI Construction and use of synthetic constructs encoding syndecan
IN Saunders, Scott, Boston, MA, United States
Bernfield, Merton, Boston, MA, United States
Kato, Masato, Boston, MA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5486599 19960123
AI US 1993-78683 19930617 (8)
RLI Continuation-in-part of Ser. No. US 1991-757654, filed on 6 Sep 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-856869, filed on 24 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-746797, filed on 12 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-331585, filed on 29 Mar 1989, now abandoned
DT Utility
FS Granted
LN.CNT 3939
INCL INCLM: 530/395.000
INCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 935/010.000; 935/047.000; 935/050.000; 935/070.000
NCL NCLM: 530/395.000
NCLS: 435/069.100; 435/069.700; 435/252.300; 435/320.100; 536/023.400; 536/023.500
IC [6]
ICM: C07K014-435
ICS: C07K019-00; C12N015-12; C12N015-62
EXF 536/23.4; 530/395; 530/350; 435/69.7; 435/69.1; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 55 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 10
AN 1994:303016 BIOSIS
DN PREV199497316016

TI Binding of urinary protein C inhibitor to cultured human epithelial kidney tumor cells (TCL-598): The role of glycosaminoglycans present on the luminal cell surface.
AU Priglinger, Ute; Geiger, Margarethe (1); Bielek, Edith; Vanyek, Erika; Binder, Bernd R.
CS (1) Lab. Clinical Experimental Physiol., Dep. Med. Physiol., Schwarzspanierstrasse 17, A1090 Vienna Austria
SO Journal of Biological Chemistry, (1994) Vol. 269, No. 20, pp. 14705-14710. ISSN: 0021-9258.
DT Article
LA English

L12 ANSWER 56 OF 64 USPATFULL
AN 93:69847 USPATFULL
TI Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
IN Zimmerman, Theodore S., La Jolla, CA, United States
Fujimura, Yoshihiro, Kashihara, Japan
Houghten, Richard A., Solana Beach, CA, United States
Ruggeri, Zaverio M., La Jolla, CA, United States
PA Scipps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)
PI US 5238919 19930824
AI US 1990-519606 19900507 (7)
RLI Continuation-in-part of Ser. No. US 1988-270488, filed on 4 Nov 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-869188, filed on 30 May 1986, now abandoned
DT Utility
FS Granted
LN.CNT 1475
INCL INCLM: 514/008.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 514/822.000; 530/324.000; 530/325.000; 530/326.000; 530/383.000; 530/395.000
NCL NCLM: 514/008.000
NCLS: 514/012.000; 514/013.000; 514/014.000; 514/822.000; 530/324.000; 530/325.000; 530/326.000; 530/383.000; 530/395.000
IC [5]
ICM: A61K035-16
ICS: A61K037-02; C07K004-08; C07K015-14
EXF 530/33; 530/330; 530/329; 530/328; 530/327; 530/326; 530/325; 530/324; 530/350; 514/8; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18; 514/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 57 OF 64 CANCERLIT
AN 94697921 CANCERLIT
DN 94697921
TI Molecular mechanism for the regulation of fibroblast growth factor by the polyanions heparin and suramin (Meeting abstract).
AU Ranson M R; Stone A L; Chen R; Porter D; Myers C E
CS Dept. of Medical Oncology, Christie Hosp., Manchester, UK.
SO Br J Cancer, (1993) 67 (Suppl XX) 11.
ISSN: 0007-0920.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Institute for Cell and Developmental Biology
EM 199403
ED Entered STN: 19941107
Last Updated on STN: 19970509

L12 ANSWER 58 OF 64 DDFU COPYRIGHT 2002 THOMSON DERWENT
AN 1993-23404 DDFU P

TI Molecular Mechanism for the Regulation of Fibroblast Growth Factor by the Polyanions Heparin and Suramin.
AU Ranson M R; Stone A L; Chen R; Porter D; Myers C E
LO Manchester, United Kingdom; Bethesda, Maryland, United States
SO Br.J.Cancer (67, Suppl. 20, 11, 1993)
CODEN: BJCAAI ISSN: 0007-0920
AV Department of Medical Oncology, Christie Hospital, Manchester, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L12 ANSWER 59 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 11
AN 1989:121985 BIOSIS
DN BA87:56638
TI BINDING OF PROTEASE NEXIN-1 TO THE FIBROBLAST SURFACE ALTERS ITS **TARGET** PROTEINASE SPECIFICITY.
AU WAGNER S L; LAU A L; CUNNINGHAM D D
CS DEP. MICROBIOL. AND MOL. GENETICS, COLL. MED., UNIV. CALIFORNIA, IRVINE, CALIF. 92717.
SO J BIOL CHEM, (1989) 264 (1), 611-615.
CODEN: JBCHA3. ISSN: 0021-9258.
FS BA; OLD
LA English

L12 ANSWER 60 OF 64 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 74150058 EMBASE
DN 1974150058
TI Distribution of sulphate and iduronic acid residues in heparin and heparan sulphate.
AU Hook M.; Lindahl U.; Iverius P.H.
CS Inst. Med. Chem., Univ. Uppsala, Sweden
SO Biochemical Journal, (1974) 137/1 (33-43).
CODEN: BIJOAK
DT Journal
FS 037 Drug Literature Index
029 Clinical Biochemistry
025 Hematology
LA English

L12 ANSWER 61 OF 64 FEDRIP COPYRIGHT 2002 NTIS
AN 2002:179021 FEDRIP
NR CRISP 5R01HL62602-03
TI NOVEL USE OF HMG-COA REDUCTASE INHIBITORS IN STROKE
SF Principal Investigator: MOKOWITZ, MICHAEL A; MASSACHUSETTS GENERAL HOSPITAL, 149 13TH STREET, CHARLESTOWN, MA. 02129
CSP MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MASSACHUSETTS
CSS Supported By: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
FYR 2001
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L12 ANSWER 62 OF 64 GENBANK.RTM. COPYRIGHT 2002

LOCUS (LOC): SCO939105 GenBank (R)
GenBank ACC. NO. (GBN): AL939105 AL109974 AL117385 AL117387 AL117669 AL121596 AL121600 AL121719 AL121849 AL121855 AL132662 AL132707 AL645882
GenBank VERSION (VER): AL939105.1 GI:24418991
CAS REGISTRY NO. (RN): 468711-59-3
SEQUENCE LENGTH (SQL): 291000

MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Bacteria
DATE (DATE): 25 Oct 2002
DEFINITION (DEF): Streptomyces coelicolor A3(2) complete genome; segment 2/29.
SOURCE: Streptomyces coelicolor A3(2).
ORGANISM (ORGN): Streptomyces coelicolor A3(2)
Bacteria; Actinobacteria; Actinobacteridae; Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces
NUCLEIC ACID COUNT (NA): 39089 a 105537 c 106715 g 39659 t
COMMENT:
On or before Oct 29, 2002 this sequence version replaced gi:20520891, gi:20520894, gi:20520895, gi:20520772, gi:20520896, gi:20520897, gi:20520883, gi:20520899, gi:20520902.
REFERENCE: 1
AUTHOR (AU): Bentley,S.D.; Chater,K.F.; Cerdeno-Tarraga,A.M.; Challis,G.L.; Thomson,N.R.; James,K.D.; Harris,D.E.; Quail,M.A.; Kieser,H.; Harper,D.; Bateman,A.; Brown,S.; Chandra,G.; Chen,C.W.; Collins,M.; Cronin,A.; Fraser,A.; Goble,A.; Hidalgo,J.; Hornsby,T.; Howarth,S.; Huang,C.H.; Kieser,T.; Larke,L.; Murphy,L.; Oliver,K.; O'Neil,S.; Rabbinowitsch,E.; Rajandream,M.A.; Rutherford,K.; Rutter,S.; Seeger,K.; Saunders,D.; Sharp,S.; Squares,R.; Squares,S.; Taylor,K.; Warren,T.; Wietzorrek,A.; Woodward,J.; Barrell,B.G.; Parkhill,J.; Hopwood,D.A.
TITLE (TI): Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2)
JOURNAL (SO): Nature, 417 (6885), 141-147 (2002)
OTHER SOURCE (OS): CA 136:396750
REFERENCE: 2 (bases 1 to 291000)
AUTHOR (AU): Bentley,S.D.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (09-MAY-2002) Submitted on behalf of the Streptomyces sequencing team, Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA E-mail: sdb@sanger.ac.uk

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..291000	/organism="Streptomyces coelicolor A3(2)" /strain="A3(2)" /db-xref="taxon:100226"
gene	213..3092	/gene="SC5G9.14" /note="SCO0305"
CDS	213..3092	/gene="SC5G9.14" /note="SC5G9.14, hypothetical protein, len: 959 aa; unknown function, similar to TR:O54182 (EMBL:AL021411) Streptomyces coelicolor hypothetical protein (913 aa), fasta scores; opt: 698 z-score: 776.6 E(): 0, 27.0% identity in 972 aa overlap. The C-terminus shows very weak similarity to eukaryotic beta-transducins e.g. SW:GBB4-MOUSE (EMBL:S86124), gnb4, Mus musculus guanine

```
289201 accgagggtg tgtccgaagg ccccccttggt ggcgctgacc gtgacgtcgt ccacgccctt
289261 ggcgaagacg ctgtgcagcg cctgcgcctc gccgaggtcg ccgagcggtg tggcggtggc
289321 gtgggcgttg acgtgctgga tctgctccgg cacgagcccc gcgtcgcgca gtgcggcgtc
289381 gacggccgcc gcgcagcccg gaccgccggg cgccggctgg gccacgtggt ggctgtcgtt
289441 ggtgatgccc gccccggtga gccggccgtg gacgcgggcg ccgcgggcgg cggcgtgcgc
289501 ggcgctctcg accacgagca tgccggcgcc ctccccccatc acgaagccgt cccggtcggc
289561 gtcgaagggc ctggaggccc ccttgggatc gtcgtggcgc cgggagaggg cccgcagccg
289621 cgcgaacccg gccaggacca gcggatgcag cgcggcctcg gtgccgcccg cgaccacgat
289681 gtccgcgcgg ccgtcccgga tcatgccgag ggcctgggcg agggcctcgg caccggcggc
289741 gcaggcactg acgggcgcgt gcaccccggc cttcgcgccc accatgagcc ccacttcggc
289801 ggccgcgtgg ttgggcagca tgaccgggat ggtgcgcggg ctcacccgcc ccgcgccctg
289861 cgtccgcagg cggtggtcct gctccaggac gctggtgagg ccgcccagcc ccaccccgac
289921 gaccacggcc acccgcgacc cgtccccggc gagcgcggac gggtcgggga accccgcgtc
289981 gcgaacggcc tcgcgggcgg ccacgagggc gaactgcgcc gagcggtcgc agtgcgccgc
290041 cttggcggac gacaggaccg tcccggggtc gaccgcggcc ggggccgcga ggtacacctg
290101 tgcgggcccg gccggctcgc cgaagtcgac gcgttcgacg ccgcacccgc cgtccagcag
290161 ggcccgccag gtggagggga cgtcgccgcc cagcgaggtg gtcagcccca gccccgtgac
290221 gacggcggcc cgctccccgg gggccgggcc ggccgcgtgt cgtggactca cgcggtgccg
290281 ccggcggggg cggcgacggc ctcggcgagg tgggcggcga tctgccgcac cgtcgtgagc
290341 cggtccgcct gctcctgggg gacctcgatc tgccagcggt cctcgatcgc ggcgaccagt
290401 tccagccggg ccagcgagtc gacgcccagg tcgtcctgga gcgaggagtc ggggccgatc
290461 tcctccacgg tcaggtcctc gaccgtggcg gcgagcaggt cacgcagctc gtcgagcagc
290521 tgtcgttcgt cggcggtgga cggcatgtcc ggtacctcct cggtcggtgc acggcgcgcc
290581 cggaggcggt gggcgggagg acccgttccc cgggcgcgcc ggtggtgtcc ggcgacctgc
290641 cggtgcacgc ggacaggctg tccggccgtg cggcacggta agcgccgggg gcggagggac
290701 ggcggagcat cgggagcacg ggacgggctc ctgcgagcac ccgtgtcccc ccttcacctt
290761 gaagcgcccc ggcgccgacc gagggtggcg ggctgcgggc gcgtaaggga ccggacgggg
290821 cgaaacgggg cgccgggcat cctcaacgga ctttggcggc tcttttaagg ctttctgaag
290881 atgaccttcg aacgggcgtt tccacgccgg tcgcgtccta ggctctcgaa cacccccccac
290941 agtcccggtg ggcgcggtcg cgtccaccgg gtacgggggt tccgccagcc gaccgacaag
```

L12 ANSWER 63 OF 64 GENBANK.RTM. COPYRIGHT 2002

LOCUS (LOC): SCF62 GenBank (R)
GenBank ACC. NO. (GBN): AL121855 AL645882
GenBank VERSION (VER): AL121855.3 GI:20520899
CAS REGISTRY NO. (RN): 244807-66-7
SEQUENCE LENGTH (SQL): 34496
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Bacteria
DATE (DATE): 12 May 2002
DEFINITION (DEF): Streptomyces coelicolor cosmid F62.
SOURCE: Streptomyces coelicolor A3(2).
ORGANISM (ORGN): Streptomyces coelicolor A3(2)
Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
Actinomycetales; Streptomycineae; Streptomycetaceae;
Streptomyces
NUCLEIC ACID COUNT (NA): 4747 a 12332 c 12742 g 4675 t
COMMENT:
On May 9, 2002 this sequence version replaced gi:6165435.
Notes:
Streptomyces coelicolor sequencing at The Sanger Centre is funded by the BBSRC and Beowulf Genomics
Details of S. coelicolor sequencing at the Sanger Centre are available on the World Wide Web.
(URL; http://www.sanger.ac.uk/Projects/S_coelicolor/) CDS are numbered using the following system eg SC7B7.01c. SC (S. coelicolor), 7B7 (cosmid name), .01 (first CDS), c (complementary strand).
The more significant matches with motifs in the PROSITE database are also included but some of these may be fortuitous. The length in codons is given for each CDS.

Usually the highest scoring match found by fasta -o is given for CDS which show significant similarity to other CDS in the database. The position of possible ribosome binding site sequences are given where these have been used to deduce the initiation codon. Gene prediction is based on positional base preference in codons using a specially developed Hidden Markov Model (Krogh et al., Nucleic Acids Research, 22(22):4768-4778(1994)) and the FramePlot program of Bibb et al., Gene 30:157-66(1984) as implemented at http://www.nih.go.jp/ jun/cgi-bin/frameplot.pl. CAUTION: We may not have predicted the correct initiation codon. Where possible we choose an initiation codon (atg, gtg, ttg or (att)) which is preceded by an upstream ribosome binding site sequence (optimally 5-13bp before the initiation codon). If this cannot be identified we choose the most upstream initiation codon.
IMPORTANT: This sequence MAY NOT be the entire insert of the sequenced clone. It may be shorter because we only sequence overlapping sections once, or longer, because we arrange for a small overlap between neighbouring submissions. Cosmid F62 Lies on the AseI-F genomic restriction fragment.

REFERENCE: 1 (bases 1 to 34496)
AUTHOR (AU): Redenbach,M.; Kieser,H.M.; Denapaite,D.; Eichner,A.; Cullum,J.; Kinashi,H.; Hopwood,D.A.
TITLE (TI): A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb Streptomyces coelicolor A3(2) chromosome
JOURNAL (SO): Mol. Microbiol., 21 (1), 77-96 (1996)
OTHER SOURCE (OS): CA 125:159753

REFERENCE: 2 (bases 1 to 34496)
AUTHOR (AU): Murphy,L.; Harris,D.
JOURNAL (SO): Unpublished

REFERENCE: 3 (bases 1 to 34496)
AUTHOR (AU): Thomson,N.R.; Parkhill,J.; Barrell,B.G.; Rajandream,M.A.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (29-OCT-1999) Streptomyces coelicolor sequencing project, Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA E-mail: barrell@sanger.ac.uk Cosmids supplied by Prof. David A. Hopwood, [3] John Innes Centre, Norwich Research Park, Colney, Norwich, Norfolk NR4 7UH, UK

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..34496	/organism="Streptomyces coelicolor A3(2)" /strain="A3(2)" /db-xref="taxon:100226" /clone="cosmid F62"
misc-feature	complement(17..1123)	/note="Pfam match to entry PF00083 sugar-tr, Sugar (and other) transporter, score -87.50, E-value 0.00097"
RBS	complement(1221..1226)	
RBS	1315..1318	
gene	1325..1927	/gene="SCF62.02" /note="SCO0376"
CDS	1325..1927	/gene="SCF62.02" /note="SCF62.02, possible transcriptional regulator, len: 200 aa. Similar to several

```
31681 cggtgcggcg cacctctgc gagcggaacc tggtcgtcgc ccggcgcgtc gaggaccagt
31741 tcgccgcgct gaccacggcg ctgttcccgg cgaccgacca cgcccacgcc ctgcgggagg
31801 caccatgaag gcgaccgaag tgccggagat ctccggcgcg tacctgttcc ggcccacgcc
31861 gcacgcggac gcacgcggat tcttctgccg cacgttcgac gccgatgtcg tccgctcggt
31921 gggtctcgac ccggccgcct tcgtccagga cagcgtgtcg cgctcggtcc ggggcgtgct
31981 gcgcggcctg cacctgcgct ccggcgccgg tgaggccaag ctggtgcggt gctccaacgg
32041 gaggatcttc gacgccgtcg tggacctgcg tgcggactcg ccgacctatc tgggccgggc
32101 gttcttcgag ctgtccggcg agacgcagac gaccctgtac atcccggcgg ggtgtgcgca
32161 cggcttccag tcgctgacgg agacctccga cgtctcgtac cggatcgacc gcgcgcacga
32221 cccggccgag gacgtgacga tcgccttcga cgacccggac ctcgccatcg actggccgct
32281 gccggtcgcc tcggtgtccc cccgggaccg ggaggcgccg agcctcgccg acttcctcaa
32341 gcacagggag ggatgagccc gaagtgaacg ccgaagaact cggtctgccc cggtcgcggc
32401 aggccaacga gcggctgcac gccctggtcc ccggcggcgc gcacacctac gccaagggcg
32461 acgaccagta cccggagaac ctggccccgg tgatcagcca cggccggggt gcccacgtgt
32521 gggacgtcga cggcaaccgc tacgtcgagt acggctccgg cctgcggtcg gtcagcctcg
32581 gccacgccca cccgcgcgtg acggaggccg tacgacggga gctcgaccgg ggcagcaact
32641 tcgtccggcc gtccatcgtg gaggtcgacg ccgcggaacg cttcctggcc acggtgccca
32701 cggcggagat ggtgaagttc gcgaagaacg gctccgacgc caccacggcg gcggtgcgcc
32761 tggcccgcgc cgccaccgga cggccccggg tggccgtctg cgccgaccat ccgttcttct
32821 cggtcgacga ctggttcatc ggcaccacgc cgatgtcggc cggcattccg gcggcgacca
32881 acgagctgac cgtggcgttc ccctacggcg acctggccgc cacggaggac ctgctcgccc
32941 ggcacgaggg cgaggtggcc tgcctgatcc tggagcccgc cacccacacc gagccgccgc
33001 ccggctacct cgccggtctg cgcgagctgg ccgaccggca cgggtgcgtc ctggtcttcg
33061 acgagatgat caccgggttc cggtggtcgg aggcgggcgc ccagggcctg tacggcgtgg
33121 tccccgacct ctccacgttc ggaaaagcgc tgggcaacgg gttcgccgtc gccgcgctgg
33181 ccgggcgccg ggagctgatg gagctcggcg gactgcggca ctccggcgac cgggtcttcc
33241 tgctgtccac cacccacggg gcggagacgc acgcgctggc ggccgcgatg gccgtgcagg
33301 gcacctacgt cgaggagggc gtcaccgcgc ggctgcacgc gctcggcgac cggctggccg
33361 ccggcgtccg ggaggccgcg gcgagcatgg gtgtcggcga ccacgtcgtc gtccggggcc
33421 gggccagcaa cctggtcttc gccaccctcg acgagaacgg gcagccgtcg cagcggtacc
33481 gcaccctgtt cctgcgccaa ctcctggcgg gcggggtgct ggcgccgtcc ttcgtggtga
33541 gcagcgcgct cggcgacgcc gacctcgacc acaccgtgga cgtggtggcc gaggcgtgtg
33601 cggtgtaccg gaaggcgctg gacgccgccg atcccacgcc ctggatggcc ggacggccgg
33661 tgaagccggt gttccgccgc ttggtgtgag gccgggcgaa ccgtggcggg gcgaaccgtg
33721 gcggggcgac gcgggccgac gtgccgtcag ctgccctgct gccgaccggc gtcggccctc
33781 cgctcggccc gccggtcgca gggcgggccg gccgtccact cgtccggcgg gtgggccggg
33841 aggccggccc accggtcggt cagccggtcg gccgtccggt cgaccagcca cgcggtgacc
33901 gggagcaccg ccagcgcggt gcaccagccg ccgagggtgt cggtcgcgta gtgggagccc
33961 agggcgacct gcgcccagcc catggccgcg ccggccacca gccccgccgc gaacacgaag
34021 gccgtgccgg ccgccctgcc gagaccgagg cgtccggccg cgagcagcga caccatgagg
34081 gcgatcgcgg tgaggaaggc ggtgtgcccg ctcgggtagg agaggttgtc gccgtggatg
34141 gtgcgcccca ccacgggttt gagcagcgtc gtcgtcccca cggtcaggcc tgcgccggtc
34201 acgacgaaca ccgccgcgcg cggatgccgg agcagcaggc agccggtcac gacggccgcg
34261 accagcagca ccgcccccgc gggctccccc aggaagtccg tgaccacggc gacgtgccgc
34321 cacggcggcc ccaccccgtc caccgccgcg aagatccgca tgtcccactc gcgcggctcg
34381 ctctcgtcgg cgtacacggc cccgaggacg aggaccaccg gcgcggcgag gcaggccatc
34441 agcacgaacc acacgcgcag ccacgacggc agcaccgcgg gccccggccg gccggt
```

L12 ANSWER 64 OF 64 MSDS-OHS COPYRIGHT 2002 MDL

OHS/MDL NUMBER: OHS95271
CAS NUMBER: 37290-86-1
SUBSTANCE: HEPARINASE III
TRADE NAME/SYNONYM: LYASE, HEPARITIN SULFATE; E.C. 4.2.2.8; HEPARAN MONOSULFATE LYASE; HEPARINASEIII FROM FLAVOBACTERIUM HEPARINUM; HEPARIN SULFATE ELIMINASE; HEPARITINSULFATE LYASE; OHS95271
CREATION DATE: Jan 15 1993
REVISION DATE: Mar 22 2001

=>
<------User Break------>